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General report of activities 1998
The European Monitoring Centre for Drugs and Drug Addiction has great pleasure
in presenting its fourth General report of activities to the European Parliament, the
European Commission and the Member States following its adoption by the
Centre’s Management Board on 15 January 1999.
The report gives a retrospective view of a year which saw the EMCDDA make
significant progress in fulfilling its tasks. Furthermore, new challenges were taken
on and cooperation in the international field intensified.
My very special thanks go to the Director and staff of the Monitoring Centre for their
work in 1998. Together with the members of the Scientific Committee and the
national focal points of the Reitox network, they succeeded in strengthening the
EMCDDA’s reputation at national, European and international level. I also wish to
thank all the members of the Management Board and their representatives for their
commitment and cooperation.
As one of the pillars of the EMCDDA’s work, the Reitox network was of special
concern to the Management Board in 1998. As a result, I am delighted that, after
intensive work, the paper on ‘The role and financing of national focal points’,
presented to the Board by the working group created specifically for this task, was
adopted unanimously in autumn 1998. In this way, the work of the national focal
points was set on a firmer foundation.
Looking back on the achievements of 1998, I am convinced that the committed,
loyal and open collaboration of all those working in and with the Centre that was
demonstrated over the course of the last year will confirm the EMCDDA’s success
in fulfilling its future tasks and challenges. I look forward to meeting the same spirit
in 1999.
Franz J. Bindert
Chairman of the EMCDDA Management Board
Foreword
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In 1998, the EMCDDA moved into a new phase with the start of its second three-
year work programme (1998-2000), designed to consolidate and build on much of
the groundwork undertaken during the first three years of the Centre’s existence.
The two priority areas of the 1998-2000 work programme are: to enhance the
Centre’s achievements in the field of demand for drugs and the reduction of that
demand; and to develop its activities in the field of national and Community
strategies and policies.
This brief introduction will not attempt to enumerate all the Centre’s achievements
in 1998, but will let the different chapters speak for themselves. It will, however,
highlight what were among the most significant changes and events of the year for
the EMCDDA.
The very real growth in both scope and scale of the EMCDDA’s activities was
illustrated over the course of the year by the increase in the number of staff
employed by the Centre which grew to 40 full-time members. In this context, an
important structural change was the creation of a new section to coordinate the
Centre’s work relating to the joint action on new synthetic drugs adopted on 16
June 1997 in Brussels by the Council of the European Union (1). A coordinator
formally responsible for this section was appointed on 1 September 1998. Among
the main results of this section’s work were: the production of ‘Guidelines on the
risk assessment of new synthetic drugs’, which were formally adopted by the
EMCDDA’s Scientific Committee in October; a detailed ‘Report on the risk
assessment of MBDB’ (the synthetic drug N-Methyl-1-(1,3-benzodioxol 5-yl)-2-
butanamine); and cooperation with Europol in establishing the joint information
reports foreseen under Article 3 (exchange of information) of the joint action.
The Reitox coordination department, strengthened by the appointment of a head of
department in July, also made great strides during the year in reinforcing the Reitox
network of national focal points on both a human and technical level. Among its
activities, it forged closer relationships with the central and east European countries
(CEECs) involved in the PHARE multi-country project on drug information systems
(DIS), and inaugurated a private website accessible only to members of the Reitox
community providing services including document-sharing and newsgroups.
Following extensive discussion throughout 1997, a working group composed of
members of the EMCDDA Management Board was established in 1998 to produce
a comprehensive paper on ‘The role and financing of national focal points’ in
consultation with the national focal points themselves. The paper states that the
network should be based on equal and open collaboration and acknowledges that
previous funding to the national focal points was inadequate for the tasks expected
Introduction
(1) Joint action concerning the ‘information exchange, risk assessment and the control of new synthetic
drugs’ (Official Journal L 167, 25.6.1997) adopted on 16 June 1997. A joint action is a decision adopted
unanimously by the EU Member States within the framework of the third pillar of the Treaty on European
Union (Cooperation in the field of justice and home affairs). Synthetic drugs are psychoactive sub-
stances produced in laboratories and not derived from natural products. They include MDMA (ecsta-
sy), other amphetamines and LSD.
of them. A new funding arrangement was therefore agreed based on a 50-50 split:
from 1999, the EMCDDA will raise its contribution to each focal point from EUR
40 000 to EUR 100 000 per annum, provided that the Member State concerned also
contributes EUR 100 000 annually to the focal point’s work. The paper was
formally adopted by the EMCDDA Management Board in October.
On 18 December, the EMCDDA launched its 1998 Annual report on the state of
the drugs problem in the European Union. The launch took place at the Federal
Ministry of Labour, Health and Social Affairs, Vienna, in the presence of Lore
Hostasch, Austrian Federal Minister for Labour, Health and Social Affairs; Marcel
Reimen, Vice-Chairman of the EMCDDA Management Board; Georges Estievenart,
Director of the EMCDDA; and Peter Hacker, Coordinator for Drug Affairs of the City
of Vienna.
During the year, the EMCDDA made its first formal contacts with regions outside
the EU, notably the United States, Latin America and central and eastern Europe.
Cooperation with the United States was marked by the visit on 17 July of General
Barry R. McCaffrey, Director of the US White House Office of National Drug
Control Policy (ONDCP), for the first US-EU Informal Drug Forum. This event was
held at the Centre’s headquarters in Lisbon with the participation of some 30 high-
level US and European officials. The Forum was followed up by a working visit in
November from John Carnevale, Director of the ONDCP’s Office of Budget,
Research and Evaluation, to discuss concrete collaboration and joint projects
between the two organisations.
The EMCDDA’s links with Latin America were strengthened in October with the
Euro-Ibero American Seminar, ‘Cooperation on drugs and drug addiction policies’,
held in Oporto, Portugal, under the chairmanship of President of the Portuguese
Republic, Jorge Sampaio, and the patronage of Vice-President of the European
Commission, Manuel Marín. The seminar was organised in cooperation with the
Portuguese Government and with the support of the European Commission and the
EMCDDA. The resulting ‘Oporto Declaration’ was annexed to the conclusions of
the subsequent Ibero-Latin American Summit and — in anticipation of the Euro-
Latin American Summit to be held in Rio de Janeiro in 1999 — suggested that the
EMCDDA could become a link between Europe and Latin America in the drugs
field and a facilitator of forums providing information and fostering the exchange of
experiences in the fields of demand and harm reduction.
In the context of the forthcoming accession to the EU of central and east European
countries, the EMCDDA increased its cooperation with the PHARE multi-country
programme for the fight against drugs, one of the priority objectives of the Centre’s
1998 work programme. The EMCDDA contributed to the evaluation of the PHARE
project on technical assistance to drug demand reduction and participated in
several seminars in central and eastern Europe in the course of the year. Another
PHARE initiative, the PHARE multi-country project on drug information systems, is
assisting the countries of central and eastern Europe in developing an information
network similar to Reitox by setting up prototype national focal points in each
participating country. During the year, these focal points became actively involved
in the Centre’s activities and for the first time provided data on the drug situation in
their countries for the EMCDDA’s 1998 Annual report on the state of the drugs
problem in the European Union, significantly broadening the report’s geographical
scope. This level of collaboration will no doubt increase as the accession process
develops and is greatly welcomed by the EMCDDA.
The Centre also hosted several visits from European bodies. Delegations from the
European Parliament’s Committee on Civil Liberties and Internal Affairs and
Committee on the Environment, Public Health and Consumer Protection visited the
8
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Centre in March and September respectively. The Parliament further demonstrated
its interest in the European drugs problem by producing two reports in 1998: one,
adopted on 16 September in Strasbourg, evaluating the EMCDDA’s 1997 Annual
report on the state of the drugs problem in the European Union; and a second,
adopted on 6 October, on enhancing European cooperation on drugs in light of the
United Nations General Assembly Special Session on Drugs (Ungass) held in New
York in June.
In 1998, it was the turn of the EMCDDA to hold the Chair of the 11 decentralised
EU agencies. In this capacity, the Centre hosted a meeting of the Directors of the
agencies in July. Among other issues, the meeting discussed ways to strengthen
inter-agency cooperation and the role these bodies should play in the accession to
the EU of the CEECs.
A major step forward for the Centre in its links with international organisations was
the signing of a Memorandum of Understanding (MOU) with the United Nations
International Drug Control Programme (UNDCP) in March. The terms of the MOU
formally establish cooperation between the two bodies and will be reviewed in
2000. A similar MOU with the Pompidou Group of the Council of Europe was
drafted in 1998 for signature during 1999. These two events will significantly
enhance the EMCDDA’s role in the field of drugs, both at European and at
international level.
The Centre’s international role was also demonstrated by its presence at the Ungass
in New York in June. The Ungass adopted a draft declaration on the guiding
principles of drug demand reduction and a political declaration in which all
Member States committed themselves to establish and implement demand-
reduction policies by the year 2008. The Director of the EMCDDA addressed the
Committee of the Whole and welcomed the guiding principles as providing ‘a real
chance to translate political intentions into concrete action and hard facts’.
Overall, 1998 was a varied and fulfilling year for the Monitoring Centre in which
advances were made both in terms of its internal structure and activities and in its
external cooperation with other regions and organisations. The international
recognition that the Centre’s work received contributed greatly to increase its
visibility to policy-makers, scientists and practitioners in the drug field. As the year
drew to a close it was particularly gratifying that the conclusions to the European
Council meeting held in Vienna in December explicitly endorsed the Centre’s role
by stating: ‘Full use should be made of the expertise of the European Monitoring
Centre on Drugs and Drug Addiction’ in developing further ‘an integrated and
balanced post-1999 drugs strategy’. The EMCDDA will do its utmost in the coming
years to develop further this expertise and to become more and more a central point
of reference in the global fight against drugs.
Georges Estievenart
Director
Introduction
10
11
General report of activities 1998
EMCDDA work
programme 1998
Consolidating and enhancing the achievements: Priority area No 1
(demand and demand reduction)
A. Collection and analysis of existing data (2)
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the 
decisions taken by the EMCDDA Management Board
B. Improvement of data-comparison methods (2)
Priority objective 3
Improving and developing reliable and comparable methods, data systems and
key indicators
C. Dissemination of data (2)
Priority objective 4
Improving the quality of the Annual report on the state of the drugs problem in
the European Union, the visibility of the work of the EMCDDA and the Reitox net-
work and the dissemination of the information collected and produced by the
EMCDDA
Priority objectives for 1998-2000
12
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D. Cooperation with European and international bodies and organisations
and with non-Community countries (2)
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activities,
avoiding any duplication of work
Developing the achievements: Priority area No 2 (national and
Community strategies and policies)
A. Collection and analysis of existing data (2)
Priority objective 6
Developing tools and methodologies for comparing interventions, legislation,
strategies and policies in the EU (including cost-effectiveness evaluation)
(2) Fundamental tasks of the EMCDDA as stated in Article 2 of its founding Regulation (EEC) No 302/93.
Priority objective 1 
Consolidating and improving the Centre’s epidemiological ... information systems
on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
Epidemiological information systems
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Early-warning system on new synthetic drugs
Priority objective 2 
Consolidating and enhancing the Reitox network in accordance with the 
decisions taken by the EMCDDA Management Board
Reitox specific projects
Chapter 1
Epidemiology
In 1998, the EMCDDA’s work in the field of
epidemiology concentrated on priority
objectives 1, 2 and 3 of the annual work
programme. Major tasks included:
synthesising epidemiological information
for the EMCDDA’s Annual report on the 
state of the drugs problem in the European
Union; developing comparable key
indicators; developing tools for more in-
depth and policy-related data analysis;
cooperation with other institutions; and
finalising an extensive range of project
reports.
1998 work programme 
Epidemiology
Priority objective 3 
Improving and developing reliable and comparable methods, data systems and
key indicators
Epidemiological key indicators
14
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Epidemiological information systems
In 1998, the epidemiology department’s work in this area included:
l collecting and registering epidemiological data from a wide range of sources
and studies;
l initiating a project to evaluate data quality;
l preparing Chapter 1 of the Annual report on the state of the drugs problem
in the European Union 1998, largely based on the national reports submitted
by the national focal points (3); and
l a range of projects to increase the policy relevance of data analysis.
Early-warning system on new synthetic drugs
In cooperation with the EMCDDA’s unit responsible for monitoring implementation
of the June 1997 joint action on new synthetic drugs, the Centre’s epidemiology
department:
l conceptualised and planned an early-warning system on new synthetic
drugs;
l developed and tested data-collection and reporting instruments in
collaboration with Europol and the Reitox network;
l collected and analysed epidemiological and social data on MBDB (N-
Methyl-1-(1,3-benzodioxol 5-yl)-2-butanamine);
l developed risk-assessment guidelines together with the EMCDDA Scientific
Committee (see Chapter 4);
l commissioned a study of the pharmacotoxicology and neuropsychology of
MBDB (contractor: Dutch focal point, Trimbos-instituut, Utrecht; timespan:
May to October 1998); and
l participated in a special risk-assessment meeting on MBDB (see Chapter 4).
Reitox specific projects
Continuing work begun under the 1996 Reitox work programme, the epidemiology
department contributed to developing, testing and implementing standards on
indicators of treatment demand and drug-related deaths (see below).
Epidemiological key indicators
In 1998, the department focused on promoting the development and subsequent
implementation of instruments and standards relating to five key indicators by
undertaking the following projects:
(3) National reports produced by the national focal points record the drug situation in an EU Member State
and provide the core data for the EMCDDA's annual report.
Drug use in the general population
Coordination of an expert working group
This project, which built on work begun in 1997, aimed to improve the quality and
comparability of general-population surveys on drugs by working with a group of
national experts from nine EU Member States. The group expanded and
consolidated instruments (standard core modules for integration into national
questionnaires) and methodological guidelines (on sampling, data-collection
analysis and reporting results). The core modules, including new ones developed
in 1998, were then translated and pre-tested in selected Member States. A joint
analysis of recent national surveys from six participating countries was also carried
out by a subgroup of the expert group (contractor: Bureau voor Onderzoek en
Statistiek (O+S), Amsterdam; timespan: December 1997 to December 1998).
Methodological study
A methodological study to compare the effects of different data-collection methods
on the prevalence of self-reported drug use in general population surveys was
carried out in parallel with the above project. Three Member States — Greece, the
Netherlands and Sweden — conducted national face-to-face surveys and telephone
and mail surveys using compatible questionnaires and sampling frames for which
extra fieldwork costs were met by the EMCDDA (contractor: Dutch, Greek and
Swedish focal points; timespan: May to November 1998). A comparative analysis
of the results obtained from the different methods was undertaken by the University
of Amsterdam (timespan: October 1997 to December 1998).
Prevalence estimates of problem drug use
Study to obtain comparable national estimates
As a follow-up to a 1997 pilot study undertaken in five Member States to identify
useful estimation methods, the recommendations were applied in Member States to
obtain comparable estimates of national prevalence of problem drug use. 
A meeting with experts from 14 EU Member States and Norway was held to discuss
the methods and data availability in each country. Estimates were obtained for 
13 countries and three additional methods were developed. Guidelines were drawn
up for applying the recommended methods using common procedures and
definitions (contractor: German Focal Point, Institut für Therapieforschung (IFT),
Munich; timespan: January to November 1998).
Project to disseminate methodological guidelines for local estimates
Building on a 1997 project to estimate the prevalence of problem drug use at local
level in seven cities using three-sample capture-recapture, guidelines were drawn
up in 1998 for applying this methodology using comparable procedures and
definitions. A ‘help desk’ of prevalence estimation experts was established to advise
local prevalence studies using this method, and local prevalence studies in the
Member States were reviewed. A practical manual is being produced based on 
the guidelines used in the project (contractor: University of Glasgow, UK 
(see http://www.gla.ac.uk/Inter/DrugMisuse/EMCDDA); timespan: January to
November 1998).
Network of national and local prevalence estimation
With the help of funding from the targeted socioeconomic research (TSER)
programme of Directorate-General XII (Science, Research and Development) of the
European Commission, a network of national and local prevalence estimation was
created to promote information exchange on estimation methods and develop
proposals for in-depth studies.
Chapter 1: Epidemiology
Demand for treatment by drug users
Feasibility study to improve treatment-reporting systems
Continuing its work on treatment-demand indicators, the Centre carried out a
feasibility study of implementing recommendations to improve the comparability of
national treatment-reporting systems in the EU. The availability of core data in all
Member States was also assessed. A meeting was held in Lisbon in July 1998 to
discuss the results of the study and plan the next steps (contractor: IFT, Munich;
timespan: November 1997 to July 1998).
Field trial of data collection
As a result of the above feasibility study, a draft EMCDDA-Pompidou Group
protocol was planned defining a routine system for collecting and reporting
standard and comparable anonymous core data on clients starting treatment. A field
trial will test how and where to implement this protocol in the Member States. Data
collected during this field trial will be used for an initial joint analysis at EU level
(contractor: IFT, Munich; timespan: November 1998 to July 1999).
Drug-related deaths and mortality among drug users
Improving the quality and comparability of data on drug-related death
statistics
This project followed on from work carried out under the 1996 Reitox work
programme. Data from General Mortality Registries (GMR) and/or Special Registries
(SR) in 14 EU Member States were analysed by comparing existing national data-
collection criteria on drug-related deaths against a set of draft guidelines from the
1996 Reitox project. As a result, revised draft guidelines for reporting results from
GMRs and SRs were drawn up. In June 1998, a meeting was held in Utrecht to
discuss the results of the project with all focal points (contractor: Trimbos-instituut,
Utrecht; timespan: November 1997 to July 1998).
Field test of the guidelines
The draft guidelines will be field tested in all Member States. The results will be
analysed both within and between countries to produce concrete proposals to
improve the quality and comparability of statistics on drug-related deaths
(contractor: Trimbos-instituut, Utrecht; timespan: November 1997 to July 1999).
Development of cohort studies
Building on the achievements of a previous review of studies of mortality among
drug users and a feasibility study for devising a common methodology for
monitoring overall and cause-specific mortality among drug users in the EU, a
revised standard protocol was promoted for use in cohort studies. This will assess
and compare general and cause-specific mortality in cohorts of drug users recruited
from treatment centres. Ongoing, new or planned studies applied this standard
protocol in 12 Member States and a preliminary joint analysis of data from selected
ongoing programmes was made (contractor: Osservatorio Epidemiologico —
Regione Lazio, Rome; timespan: January to October 1998).
Implementation, follow-up and analysis
The EMCDDA will continue to ensure coordinated implementation, follow-up and
analysis of cohort studies on mortality among drug users in the EU. A more in-depth
comparative analysis will be conducted for groups that have completed a
significant follow-up period (contractor: Osservatorio Epidemiologico — Regione
Lazio, Rome; timespan: November 1998 to October 1999).
16
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Infectious diseases among drug injectors
Improving data quality for surveillance
Following a 1997 study to review literature on drug-related infectious diseases and
collect information on data sources and levels of infection in five Member States, a
project began in 1998 to improve data quality for the surveillance of hepatitis B and
C and HIV infection in injecting drug users. This project will evaluate available data
in all Member States and draw up recommendations to improve the monitoring of
the spread of infectious diseases in such drug users using comparable methods and
definitions (contractor: University of Glasgow, UK; timespan: December 1998 to
September 1999).
Other activities in the field of epidemiology
Analysing data for decision-makers
In 1998, the epidemiology department began various projects to develop and apply
tools for in-depth and policy-relevant analysis of data on drug use. In particular,
these focused on:
l dynamic modelling;
l qualitative research; and
l new trends.
Dynamic modelling
Incidence of problem drug use and time trends in indicators
A pilot project was begun in 1998 to analyse the incidence of problem drug use in
three cities using back-calculation methods and drug-treatment data. The time lag
between the onset of drug use and first demand for treatment was estimated, as
were the factors determining the length of this period and the typical treatment
history of drug users in the different cities. Comparisons were made with time- and
age-related information from other indicators such as drug deaths and police arrests
(contractor: University Tor Vergata, Rome; timespan: July 1998 to February 1999).
Geographic spread of drug use
A study was also launched to develop an explanatory model, database and maps
showing the geographical diffusion of drug use and spatial distribution of indicators
in the EU. At a project meeting in Lisbon on 4 and 5 December 1998, maps of drug-
related data from different parts of Europe (e.g., treatment, drug-related deaths)
were examined and the use of geographical information systems to develop more
sophisticated analyses of drug use was discussed (contractor: Keele University, UK;
timespan: July 1998 to February 1999).
Networks of modelling of incidence and time trends and of geographic
spread
With funding from the European Commission’s TSER programme, the Centre
created two networks for modelling incidence and time trends in problem drug use,
and for mapping and modelling the geographic spread of drug use. These networks
will facilitate the exchange of information on ongoing work, the development of
comparable methods and data standards, and the creation of in-depth studies on
the temporal and spatial diffusion of drug use (contractors: University Tor Vergata,
Rome, and Keele University, UK; timespan: December 1998 to December 2000).
Chapter 1: Epidemiology
Social costs of drug use
A project was initiated to estimate the impact and costs of hepatitis B and C and
HIV infection in injecting drug users in the EU. The project will assess the
epidemiological impact and development of hepatitis B and C and HIV in injecting
drug users and their likely implications for current and future health-care costs
compared to those of other diseases. Policy options for health interventions for
hepatitis B and C and HIV will be analysed, such as the cost-effectiveness of
different prevention and treatment initiatives (contractor: Netherlands National
Institute of Public Health and the Environment (RIVM), Bilthoven; timespan:
November 1998 to September 1999).
Network of modelling costs of drug use and cost-effectiveness of 
interventions
With funding from the European Commission’s TSER programme, the Centre set up
a network of experts in the field of modelling costs of drug use and cost-
effectiveness of interventions. This network will exchange information on ongoing
work, develop comparable methods and data standards, and develop proposals for
in-depth studies into the costs of drug use and the cost-effectiveness of different
interventions, such as prevention and treatment (contractor: RIVM, Bilthoven;
timespan: December 1998 to December 2000).
Network of economic analysis of drug markets and interventions
Also with funding from the TSER programme, the Centre set up a network of experts
in the field of economic analysis of drug markets using dynamic modelling. The aim
is to exchange information on ongoing work, to develop comparable methods and
data standards, and to develop proposals for in-depth studies into the relationship
of drug use to market indicators and options for policy interventions, such as law
enforcement (contractor: University of York, UK; timespan: December 1998 to
December 2000).
Scientific seminar and monograph
A scientific seminar, ‘Drug use research, policy and dynamic modelling’ was held
in Lisbon from 7 to 9 May. The seminar broadened the network of modelling
experts, discussed policy-relevant applications of dynamic modelling and identified
ideas for future projects. A scientific monograph, Dynamic models of drug use and
drug problems, presenting a comprehensive overview of the use of dynamic
modelling in drug use research following a 1997 review project, was prepared for
publication (contractor: University of York, UK; timespan: November 1997 to June
1998).
Qualitative research
Working groups of qualitative researchers
A project to coordinate working groups of qualitative researchers to analyse
patterns of drug use and their implications for public-health strategies and
prevention was undertaken in 1998. This project built on previous work (an
inventory, bibliography and synthesis of qualitative research in the EU), and created
three working groups to review research on drug trends and youth, drugs and
crime, and risk behaviours and health. A web site was created at
http://www.qed.org.uk, which became a key project tool (contractor: National
Addiction Centre (NAC), London; timespan: December 1997 to November 1998).
Scientific seminar
In the context of this project, a scientific seminar, ‘Qualitative research: Knowledge
for effective action’, was hosted by the EMCDDA from 29 to 31 October 1998. The
seminar examined how to promote the value of qualitative research in better
understanding drug use (and as a tool for planning rational interventions), and
assessed proposals on the key topics reviewed by the project. The meeting brought
together qualitative researchers and policy-makers from throughout Europe as well
18
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as from several international organisations. Results of the project on qualitative
research were presented, including an updated overview of the state of the art in
this type of research in the EU, and in-depth revisions of qualitative research
findings (contractors: NAC, London, for coordination of contents; and Traducta,
Lisbon, for organisation).
New trends
Identifying, tracking and understanding emerging trends
In 1998, work in this area complemented and provided a broader framework for
the early-warning system on new synthetic drugs (see Chapter 4). A feasibility study
was carried out to improve the sensitivity of monitoring systems (local, national and
European) to emerging drug trends and problems. Existing monitoring methods and
models were reviewed and the situation in France, Germany, the Netherlands,
Spain and the UK assessed. The results were synthesised and proposals for
improvements made to the Reitox network. The next step is to test and implement
the proposals in conjunction with the national focal points and other European
networks (contractor: NAC, London; timespan: December 1997 to July 1998).
Further projects
Four further epidemiological projects were started in 1998:
l a literature review on the relation between illicit drug use and impaired
driving and traffic accidents (contractor: Irish Focal Point, Health Research
Board, Dublin; timespan: July 1998 to January 1999);
l a literature review of published and ongoing research into risk factors for
initiation into and experimentation with drugs, the development of
problematic use and implications for interventions (contractor: Centre for
Research on Drugs and Health Behaviour, London; timespan: June to
December 1998);
l a literature review and synthesis of research on drug-related non-fatal
emergencies seen by hospitals and ambulance services. Potential uses of this
information were evaluated, including for detecting new drugs (contractor:
Institut Municipal d’Investigació Mèdica (IMIM), Barcelona; timespan:
March to December 1998); and
l a small expert meeting was held on 7 December to develop ideas for future
work on social and socioeconomic aspects, focusing on social exclusion.
Developing cooperation with other institutions
In the field of epidemiology, cooperation was developed with a wide range of
partners. These included:
l Directorates-General I (External Relations), V (Employment, Industrial
Relations and Social Affairs), VII (Transport) and XII (Science, Research and
Development) of the European Commission;
l the World Health Organisation;
l the United Nations International Drug Control Programme;
l the Pompidou Group of the Council of Europe;
l Europol;
l the European Centre for the Epidemiological Monitoring of AIDS, Paris; and
l the European Agency for the Evaluation of Medicinal Products (EMEA),
London.
Chapter 1: Epidemiology
Reports and output of projects, 1998
Epidemiology
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Epidemiological key indicators
Drug use in the general population
l Coordination of an expert working group to develop instruments and
guidelines to improve quality and comparability of general population
surveys on drugs
l ‘Methodological study to compare the effects of different data-collection
methods on the prevalence of self-reported drug use in general population
surveys’
Prevalence estimates of problem drug use
l ‘Study to obtain comparable national estimates of problem drug use
prevalence for all EU Member States’
l Project to disseminate methodological guidelines to estimate the
prevalence of problem drug use on the local level
Demand for treatment by drug users
l ‘Feasibility study on implementing the recommendations of Reitox sub-
tasks to improve the comparability of national treatment reporting systems
in the Member States’
Drug-related deaths and mortality among drug users
l ‘Improving the quality and comparability of data on drug-related deaths in
the EU Member States’
l Coordination to develop cohort studies on mortality among drug users
Analysing data for decision-makers
Modelling
l Report of the seminar, ‘Drug use research, policy and dynamic modelling’
l Dynamic models of drug use and drug problems, EMCDDA scientific
monograph No 4 (Lisbon: EMCDDA, in press)
Qualitative research
l Coordination of working groups of qualitative researchers to analyse drug-
use patterns and implications for public health strategies and prevention
l Report of the seminar, ‘Qualitative research: Knowledge for effective
action’
l Qualitative research website at http://www.qed.org.uk
New trends
l ‘Feasibility study on detecting, tracking and understanding emerging
trends in drug use’
Other projects
l ‘Literature review on the relation between drug use, impaired driving and
traffic accidents’
l ‘Literature review on risk factors for drug use and problem use’
l ‘Review and synthesis of scientific literature on drug-related non-fatal
emergencies’
Major meetings organised by the EMCDDA, 1998
Epidemiology
l EMCDDA scientific seminar, ‘Drug use research, policy and dynamic
modelling’, Lisbon, 7 to 9 May
l EMCDDA expert meeting, ‘Drug-related deaths information’, Utrecht, 29
and 30 June
l EMCDDA expert meeting, ‘Treatment demand information’, Lisbon, 6 and
7 July
l Fifth international epidemiology working group (IEWG), Lisbon, 21 to 23
July
l Working group on alcohol, drugs, medicines and driving of Directorate-
General VII (Transport) of the European Commission, Lisbon, 28 and 29
September
l EMCDDA scientific seminar, ‘Qualitative research: Knowledge for effective
action’, Lisbon, 29 to 31 October
l EMCDDA project meeting, ‘Geographic spread of drug use’, Lisbon, 4 and
5 December
l EMCDDA expert meeting, ‘Social exclusion and drugs’, Lisbon, 7
December
Major meetings attended by the EMCDDA, 1998
Epidemiology
l PHARE meeting, ‘Drug information systems’, Amsterdam, 16 and 17
March
l Wilton Park Conference, ‘Drugs and their impact on crime: Europe’s
response’, Steyning, West Sussex, 6 to 8 April
l Scientific and technological contributions to the assessment of policy
options on drug use and related problems, European Parliament, Brussels,
23 and 24 April
l Royal Statistical Society special issues meeting, ‘Drugs and criminal
statistics’, London, 6 May
l European Harm-Reduction Conference, Utrecht, 3 to 5 June
l 28th meeting of the group of experts in the epidemiology of drug
problems, Strasbourg, 8 and 9 June
l World Health Organisation-National Institute on Drug Abuse, global
research network of HIV prevention in drug-using populations, Geneva, 
25 and 26 June
l 12th World AIDS Conference, Geneva, 28 June to 3 July
l Meeting, ‘Health of intravenous drug users: Comparative study of four
European port-side towns’, Marseilles, 3 October
l Special risk-assessment meeting (extended EMCDDA Scientific
Committee), EMCDDA, Lisbon, 9 and 10 November
l Third International Hepatitis C Conference, London, 17 November
l European seminar, ‘Women, labour and drug addiction’, Lodi, Milan, 20
and 21 November
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Articles published, 1998
Epidemiology
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l Domingo-Salvany, A., Hartnoll, R. L., Maguire, A., Brugal, M. T., Albertin,
P., Caylà, J. A., Casabona, J., and Suelves, J. M., ‘Analytical considerations
in the use of capture-recapture to estimate prevalence: Case studies of the
estimation of opiate use in the metropolitan area of Barcelona, Spain’,
American Journal of Epidemiology, Vol. 148, No 8, October 1998, pp.
732-740
l Barrio Anta, G., Rodríguez Arenas, M. A., de la Fuente de Hoz, L., Royuela
Morales, L., y Grupo de Trabajo para el Estudio de Urgencias por
Psicoestimulantes (Domínguez, M., Matía, J., Vicente, J., y Sebastián, E.),
‘Urgencias en consumidores de cocaína en varios hospitales españoles:
primeras evidencias de complicaciones agudas por consumo de crack’,
Medicina Clínica (Barcelona), Vol. 111, pp. 49-55
l Hartnoll, R., ‘Epidemiology, prevention and evaluation’ in Evaluating drug
prevention in the European Union, EMCDDA scientific monograph No 2
(Lisbon: EMCDDA, 1998)
l Houweling, H., Heisterkamp, S. H., Wiessing, L. G., Coutinho, R. A., van
Wijngaarden, J. K., and Jager, H. J. C., ‘Methods for estimating HIV
prevalence: a comparison of extrapolation from surveys on infection rate
and risk behaviour with back-calculation for the Netherlands’, European
Journal of Epidemiology, Vol. 14, No 7, October 1998, pp. 645-652
l Kretzschmar, M., and Wiessing, L. G., ‘Modelling the spread of HIV in
social networks of injecting drug users’, AIDS, Vol. 12, No 7, pp. 801-811
l Vicente, J., Wiessing, L., Carpentier, C., and Hartnoll, R., ‘Prevalence and
patterns of drug use in the European Union and associated problems, in
Epidemiological trends in drug abuse: Proceedings of the Community
epidemiology work group, NIH Publication, No 99-4301 (Rockville, MD:
National Institute on Drug Abuse, in press)
1998 work programme
Demand reduction
Chapter 2
Demand
reduction
In 1998, the EMCDDA’s work in the field of
demand reduction corresponded primarily
to priority objectives 1, 2, 3 and 5 of the
annual work programme. In addition, the
EMCDDA actively participated in the
preparations for the UN General Assembly
Special Session on Drugs (Ungass) held in
June. The session’s declaration on drug
demand reduction will be followed up by an
action plan to which the EMCDDA will
contribute. Through its participation in
national and regional meetings, the demand
reduction department expanded its network
of contacts and publicised its activities
which are increasingly recognised both by
policy-makers and practitioners in the field.
Priority objective 1
Consolidating and improving the Centre’s … demand-reduction information
systems on the basis of agreed sets of core data 
(a) Current trends and patterns: monitoring traditional illicit drugs
Demand-reduction information system
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Demand-reduction responses to new trends in synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the
decisions taken by the EMCDDA Management Board
Reitox specific project to develop the network in the field of demand
reduction
Priority objective 3
Improving and developing reliable and comparable methods, data systems and
key indicators
Demand-reduction evaluation guidelines and instruments
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activities,
avoiding any duplication of work
Structured synergies and coordination with EU bodies and programmes
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Demand-reduction information system
Updating comprehensive demand-reduction data on drugs
During the first nine months of the year, the demand reduction department
analysed the data submitted by the national focal points via their information 
maps (4) and national reports for inclusion in the Annual report on the state of the
drugs problem in the European Union 1998.
Exchange on drug demand reduction activities (EDDRA)
In 1998, the EDDRA information system became accessible via the Internet at
http://www.emcdda.org/html/demand_reduction.html/. All the Reitox national
focal points participated in the feasibility phase, and the questionnaire used to
collect data was translated into the 11 EU languages. This stage identified the
criteria for selecting projects, and each focal point entered at least five programmes
into the database. By the end of the feasibility phase, EDDRA contained 120
projects. The system has elicited great interest from both professionals in the field
and policy-makers and has helped to demonstrate that the focal points provide a
service rather than simply demanding information.
At its 13th meeting in July, the EMCDDA Management Board decided that
implementing EDDRA should become a Reitox core task (see Chapter 3).
The Luxembourg focal point, the Department for Socio-Therapeutic Action of the
Ministry of Health, was contracted to add different linguistic versions and search
tools to EDDRA, make technical improvements and maintain the system. The next
major challenge is to improve the quality of the information it contains.
(4) An information map is an instrument devised by the EMCDDA in 1996 to record in detail the sources,
availability, quality and flow of information in the different EU Member States.
Inventory of training facilities
To complement its inventory of university training facilities (see
http://www.emcdda.org/html/demand_reduction.html), the EMCDDA launched a
study into non-university vocational training. This study will:
l give students an overview of training possibilities in the EU;
l give professionals involved in training a forum for exchanging experiences
and networking; and
l give decision-makers an overview of available training options.
Internet access to the inventory is being planned to make it available to a broader
public (contractor: Dutch focal point, Trimbos-instituut, Utrecht; timespan:
September 1998 to May 1999).
Evaluation Instrument Bank
A study into collecting and analysing evaluation instruments in the field of drug
prevention was finalised in 1998. A second study, focusing on treatment evaluation
instruments, was contracted to the European Institute for the Investigation of Risk
Factors for Children and Adolescents (IREFREA), Spain (timespan: January to
September 1999).
To increase the accessibility of the Evaluation Instrument Bank, an Internet-based
database of documents containing the evaluation instruments collected is being
developed. This Bank will enable users to identify the most suitable evaluation tool
for their needs and will be designed to allow for future expansion (contractor:
Luxembourg focal point, Department for Socio-Therapeutic Action, Ministry of
Health, Luxembourg; timespan: December 1998 to June 1999).
Demand-reduction responses to new trends in synthetic drugs
A follow-up to the study published in 1997 in the EMCDDA Insights series as New
trends in synthetic drugs in the European Union was launched in 1998 (contractor:
Sozialpädagogisches Institut (SPI), Berlin; timespan: December 1998 to June 1999).
Since New trends in synthetic drugs was published, additional intervention projects
have emerged with new strategies based on the fluctuating character of both the
phenomenon and the consumer population. SPI’s follow-up research will identify
the innovative characteristics, objectives, methodology and target groups of these
new demand-reduction programmes and may also examine their evaluation.
Reitox specific project to develop the network in the field of
demand reduction
The Swedish focal point, the National Institute for Public Health, is coordinating a
study to investigate how to establish new, and consolidate existing, information
networks on drug demand reduction in the EU Member States. The study will be
carried out by the Austrian, Dutch, Irish, Spanish and Swedish national focal points
and will result in an overview of current networking practice with concrete
recommendations to help all focal points (contractor: Swedish focal point, National
Institute of Public Health, Stockholm; timespan: September 1998 to June 1999).
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Demand-reduction evaluation guidelines and instruments
Guidelines for the evaluation of prevention
With the ‘Guidelines for the evaluation of drug prevention’ now available to
practitioners as a working document in all 11 EU languages, the EMCDDA has
launched a project for the guidelines’ controlled implementation (contractors:
Centro de Estudios sobre la Promoción de la Salud (CEPS), Madrid, in cooperation
with the German focal point, Institut für Therapieforschung (IFT), Munich;
timespan: September 1998 to March 1999).
Practitioners who receive the guidelines are encouraged to complete and return a
feedback sheet. On the basis of this feedback, a sample of programmes will be
contacted for further information and the guidelines revised accordingly.
Counselling is provided to programmes working with the guidelines by different
European partners involved in their development and testing.
The English-language version of the ‘Guidelines for the evaluation of drug
prevention’ was published as the first in a new series of EMCDDA manuals in
October (see Chapter 5).
Guidelines for the evaluation of treatment
One conclusion of the first EMCDDA workshop on evaluating treatment held in
Athens in March 1997 was to enhance cooperation with other international
organisations. Cooperation with the European Commission’s COST-A6 working
group on evaluation of treatment in Europe included several meetings to discuss
guidelines for the evaluation of treatment. Publication of these guidelines is
planned in the EMCDDA Manuals series for 1999.
Evaluation of substitution treatment
A study on substitution treatment was begun in 1998 (contractor: Osservatorio
Epidemiologico — Regione Lazio, Rome, in cooperation with the National
Addiction Centre (NAC), London; timespan: September 1998 to May 1999). This
study will:
l map European practice in substitution treatment by developing a typology of
substitution-treatment interventions;
l assess the state of the art of substitution treatment evaluation in Europe; and
l identify gaps in evaluation practice and methodology, paying special
attention to the interaction between substitution treatment and
accompanying assistance measures and to the long-term follow-up of
substitution clients.
The research will also define the needs of substitution treatment services for specific
evaluation guidelines.
Qualitative research in demand reduction
Current research into drug demand reduction is mainly limited to evaluating
specific projects or programmes. To redress the balance, the EMCDDA has
launched a study focusing on the mechanisms of drug demand-reduction action,
that is, the processes, actors, structural and organisational issues involved
(contractor: Nordic Council for Alcohol and Drug Research, Helsinki; timespan:
December 1998 to November 1999). By identifying individual projects and
researchers, the study will provide an overview of ongoing research and existing
literature. It will also promote further investigations and new research networks.
This work complements the epidemiology department’s study on qualitative
research on drug users (see Chapter 1).
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Structured synergies and coordination with EU bodies and
programmes
PHARE multi-country programme for the fight against drugs
In 1998, the EMCDDA participated in the evaluation group of the PHARE project
on technical assistance to demand reduction, part of the multi-country programme
for the fight against drugs. The evaluation focuses on:
l networking in four sub-regional projects;
l policy-making; and
l capacity building.
See also Chapter 8.
Cooperation with the World Health Organisation in evaluating
demand-reduction activities
The World Health Organisation (WHO) has been preparing a set of workbooks on
evaluating demand reduction. These include two basic workbooks (Planning
evaluation research and Implementing evaluation research) and six specialised
workbooks (Needs assessment evaluations, Process evaluations, Cost evaluations,
Client satisfaction evaluations, Outcome evaluations and Economic evaluations).
The EMCDDA is testing and distributing these workbooks on behalf of the WHO.
A first training workshop — organised by the EMCDDA, the WHO and the United
Nations International Drug Control Programme (UNDCP) — was held in Reggio
Emilia, Italy, in June with the participation of Ireland, Italy and Spain. The
workbooks will also be distributed to a limited number of centres which will test
the books without training. The books will be assessed via a questionnaire at the
beginning of the test phase, at six months and at 12 months before being revised
and finalised, probably by the end of 1999.
Other activities in the field of demand reduction
Alternatives to imprisonment for drug addicts
This study was commissioned by the Office of Drug Addiction of the Basque
Government to describe the existing legal framework in this domain in the EU. The
report confirms that all Member States do foresee alternative measures to prison for
drug addicts and describes their application, allowing comparisons to be drawn
between the current legislation and the practical application of alternatives to
prison. Few studies have assessed the application of these measures, since
evaluating their effectiveness compared to the results of custodial sentences poses
methodological and theoretical problems (contractor: Instituto Deusto de
Drogodependencias (IDD), University of Deusto, Spain; timespan: December 1998
to November 1999).
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Concepts, terminology and practice in the field of outreach work
This report:
l describes the role and nature of outreach work in national policies;
l identifies different models of outreach work and their various actors and
structures; and
l analyses the terminology used in different countries.
The study recognises the need for evaluation — both within individual projects and
at regional, national or European levels — even though in practice assessing such
projects is still rare in many countries. When undertaken, process evaluation
appears to be the method most frequently applied. In sum, the most urgent need of
the outreach projects themselves seems to be to improve the actual practice of such
work (contractors: Bureau voor Onderzoek en Statistiek (O+S), Amsterdam, in
cooperation with the Centre for HIV/AIDS and Drug Studies (CHADS), Edinburgh,
and Recherches et Evaluations Sociologiques sur le Social, la Santé et les Actions
Communautaires (RESSCOM), Paris; timespan: October 1997 to December 1998).
European Drug Prevention Week
The EMCDDA was actively involved in planning and implementing the third
European Drug Prevention Week (EDPW) from 16 to 22 November (see also
Chapter 8). In response to the request of Directorate-General V (Employment,
Industrial Relations and Social Affairs) of the European Commission for advice on
evaluating the EDPW, the Centre proposed using the EDDRA questionnaire as a
standard reporting instrument and to provide EDPW programmes with the
‘Guidelines for the evaluation of drug prevention’. Projects that comply with the
EDDRA quality criteria will subsequently be entered into the database.
Reports and output of projects, 1998
Demand reduction28
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Demand-reduction information system
l ‘Final report on the information system on drug demand reduction
activities — EDDRA. Revision and implementation in all EU Member
States’
Demand-reduction evaluation guidelines and instruments
l ‘Guidelines for the evaluation of drug prevention’, working document
available to practitioners electronically or on paper in all 11 EU languages
l Evaluating drug prevention in the European Union, EMCDDA scientific
monograph No 2 (Lisbon: EMCDDA, 1998)
l Guidelines for the evaluation of drug prevention, EMCDDA Manuals series
No 1 (Lisbon: EMCDDA, 1998)
l Evaluating the treatment of drug abuse in the European Union, EMCDDA
scientific monograph No 3 (Lisbon: EMCDDA, 1998)
l ‘Evaluation Instrument Bank: Core scales, sources and guidelines’
Other projects
l Study on alternatives to prison (Bilbao: Secretaría de Drogodependencias,
1998)
l ‘Outreach work among drug users in Europe: Concepts, practice and
terminology’
Major meetings organised by the EMCDDA, 1998
Demand reduction
l Expert meeting, ‘Concepts, terminology and practice in the field of
outreach work’, Amsterdam, 29 to 31 March
l WHO-EMCDDA-UNDCP joint workshop, ‘Cost effectiveness of drug
abuse treatment’, Reggio Emilia, 22 to 26 June
l Expert meeting, ‘Alternatives to prison for drug users’, Bilbao, 26 June
l Final seminar, ‘Drug treatment systems in an international perspective:
Drugs, demons and delinquents’ in cooperation with the Swiss Institute for
the Prevention of Alcohol and Drug Problems, Lisbon, 7 to 9 October
Major meetings attended by the EMCDDA, 1998
Demand reduction
l Workshop, ‘Drugs, development and cooperation’, Bilbao, 27 to 30
January
l Training seminar, ‘Drug use and the crisis of European societies’, Bologna,
5 to 7 February
l Conference, ‘Prisons and drugs’, Oldenburg, 12 to 14 March
l Meeting to prepare the United Nations General Assembly Special Session
on Drugs (Ungass), Vienna, 18 and 19 March
l Meeting of the COST-A6 working group on evaluation of treatment, Rome,
20 and 21 March
l Pompidou Group seminar, ‘Ecstasy and other drugs consumed in
discotheques’, San Marino, 26 and 27 March
l Meeting of major donors to the World Health Organisation and other
interested parties, World Health Organisation, Geneva, 8 April
l First regional seminar of the PHARE project on technical assistance to drug
demand reduction, Warsaw, 16 to 18 April
l Scientific and technological options assessment (STOA) seminar, ‘Drug
use’, Brussels, 24 April
l Conference ‘Pan-European platform against drugs’, Natolin, 25 April
l First methodological seminar of the PHARE project on technical assistance
to drug demand reduction, Sofia, 28 to 30 May
l UK Presidency drug prevention conference, Brighton, 18 and 19 May
l Seminar, ‘Ten years of development of the municipal plan against drugs of
the municipality of Madrid’, Madrid, 16 and 17 June
l Transnational Eurodyce project, First transnational coordination committee
meeting, Barcelona, 19 and 20 June
l Meeting of the steering group, ‘Costs and effectiveness of drug abuse
treatment’, Geneva, 19 August
l Seminar, ‘Addiction concepts and their impact on prevention and
treatment’, Zurich, 24 to 26 August
l Nordic Drug Conference, Vedbaek, 26 to 28 August
l Meeting of the evaluation group of the PHARE project on technical
assistance to drug demand reduction, Vienna, 12 October
l Conference, ‘Drug prevention and drug policy’, Vienna, 5 and 
6 November
l Seminar, ‘The evaluation of drug interventions’, Milan, 11 November
l ‘Congreso Europeo sobre Prevención de las Drogodependencias’, Madrid,
19 to 21 November
Chapter 2: Demand reduction
l Seminar, ‘Harm reduction in prison’, PHARE project on technical
assistance to drug demand reduction, Portoroze, Slovenia, 19 to 21
November
l Seminar, ‘Drugs — New realities’, Lisbon, 20 November
l Seminar, ‘Peer education’, Odense, 20 November
l European seminar to mark the 10th anniversary of the European Institute
for the Investigation of Risk Factors for Children and Adolescents
(IREFREA), Coimbra, 10 to 12 December
l Meeting on the UNDCP action plan on drug demand reduction, Vienna,
14 to 16 December
l IV Jornadas sobre Prevención Municipal de las Drogodependencias,
Alcorcón, Madrid, 17 and 18 December
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Articles published, 1998
Demand reduction
l Nilson, M., ‘Behandlungpolitik in Europa heute: Übersicht und Ausblick’,
Wiener Zeitschrift für Suchtforschung, Vol. 21, No 2/3, pp. 101-107
l Burkhart, G., ‘L’EMCDDA: Campi di intersezione’, Dolentium Hominum,
No 38, Anno XIII, No 2, 1998, pp. 70-72
l Burkhart, G., Termos críticos e definições na área das toxicodepêndencias.
A comunicação social e a toxicodependência (Lisbon: CENJOR, 1998)
l Merino, P. P., ‘Actividades de reducción de la demanda en relación al
éxtasis en los Estados Miembros de la UE’, in Drogas de síntesis: nuevos
patrones de ocio y consumo en los jóvenes (Santander: Consejería de
Sanidad, Consumo y Bienestar Social de Cantabria, 1998)
l Merino, P. P., ‘Hacia dónde camina la intervención sobre las drogode-
pendencias?’, in La reducción de riesgos como meta global, en busca de
la complementariedad de objetivos (Madrid: GID, 1998)
l Merino, P. P., ‘Treatment-evaluation literature’, in Evaluating the treatment
of drug abuse in the European Union, EMCDDA scientific monograph 
No 3 (Lisbon: EMCDDA, 1998)
1998 work programme
Reitox
Chapter 3
Reitox
coordination
The primary work of the Reitox coordination
department in 1998 came under priority
objectives 2 and 5 of the work programme(5).
In addition to these tasks, the department
was further strengthened by the
appointment of a new head in July and full-
time secretarial support in September.
During the year, the EMCDDA Management
Board also finalised a paper on ‘The role
and financing of national focal points’
following discussions with representatives
of the focal points since late 1996.
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the
decisions taken by the EMCDDA Management Board
Core tasks
Specific projects
Joint action on new synthetic drugs and the Reitox network
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with other EU programmes and
activities, avoiding any duplication of work
Further involvement of the CEECs in the activities of the EMCDDA and
Reitox
(5) The Reitox network consists of one national focal point from each European Union Member State, one
from the European Commission and one observer focal point from Norway.
Core tasks
In 1998, the Reitox focal points had four core tasks and two additional activities:
l updating the 1997 national reports;
l updating the 1997 information maps (sections relating to epidemiology and
documentation centres);
l active participation in the exchange on drug demand reduction action
(EDDRA) electronic information system (see Chapter 2);
l active participation in the implementation of the joint action on new
synthetic drugs;
l participation in the development of a common electronic network; and
l dissemination of the EMCDDA’s publications and products.
National reports
In preparation for the Annual report on the state of the drugs problem in the
European Union 1998, the focal points updated their national reports and
submitted them to the EMCDDA between February and July. This timescale meant
that the annual report was published considerably later than in previous years and
launched only on 18 December (see Chapter 5). In the context of the annual report
1999, guidelines for compiling the national reports were submitted in draft form to
the focal points early in November 1998 and in a final form later that month.
Information maps
Updated information maps were submitted by the focal points between February
and November 1998, although not all national centres participated.
Exchange on drug demand reduction action (EDDRA)
At their meeting in June, the heads of the Reitox focal points congratulated the
Centre on the progress made in implementing the EDDRA feasibility phase and
agreed on the importance of designating the project a Reitox core task.
Joint action on new synthetic drugs
See below and Chapter 4.
Common electronic network
In May 1998, the IDA-Reitox electronic communication environment became
operational (see Chapter 5) (6). This network was welcomed by the focal points as
a user-friendly system and a major improvement. IDA II is likely to provide the basis
for future access to the Reitox network by the central and east European countries
(CEECs).
The private Reitox website introduced in 1998 as part of the IDA project has
become a fundamental instrument for communication in the Reitox community and
ensures:
l secure e-mail communication;
l transfer of minutes, documents, papers and data;
l agenda consulting; and
l participation in newsgroups.
Access is restricted to members of the Reitox community.
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(6) The interchange of data between administrations (IDA) programme, managed by Directorate-General III
(Industry) of the European Commission, was established to coordinate the development and imple-
mentation of telematics applications and services to enable national and European administrations to
exchange information on such areas as health care, social security and employment services, public
procurement, trademarks and customs.
Dissemination of the EMCDDA’s publications and products
The focal points became more involved in the dissemination of EMCDDA
publications and products during 1998.
Reitox specific projects
The number of Reitox specific projects per year largely depends upon EMCDDA
Management Board priorities, the needs of individual departments and the work of
the Centre as a whole, as well as on discussions with the national focal points. A
number of existing projects were integrated into the Reitox work programme in
1998, and their number may increase in 1999 as the Centre incorporates further
initiatives into the network and decentralises responsibility for their management to
appropriate national focal points.
The following Reitox specific projects were undertaken in 1998:
l developing, testing and implementing standards on treatment-demand
indicators;
l developing, testing and implementing standards on indicators of drug-
related deaths;
l developing linguistic equivalents in the annual report, information maps,
EDDRA and Reitox website;
l developing the network in the field of demand-reduction activities;
l developing EDDRA on a technical level (software development for
multilingual version);
l collecting and listing non-academic vocational training facilities in the field
of drug demand reduction;
l developing a database on drug demand-reduction training facilities;
l ensuring liaison between the EMCDDA and the United Nations International
Drug Control Programme (UNDCP);
l evaluating the quality of the epidemiological information provided in the
information maps and national reports; and
l assisting the EMCDDA in the implementation of the joint action on new
synthetic drugs.
The joint action on new synthetic drugs and the Reitox network
Priority objective 2 of the work programme tasks the Centre with involving the
Reitox network in the implementation of the joint action on new synthetic drugs.
Via a questionnaire, the national centres provided information both on MBDB (N-
Methyl-1-(1,3-benzodioxol 5-yl)-2-butanamine) and on the structure, partners and
budget required for implementing the early-warning system on new synthetic drugs.
At the Reitox meeting in February 1998, the implementation of the joint action was
discussed and the participants examined the specific aims of the early-warning
system as well as how to improve the overall monitoring of new trends and patterns
of drug use as outlined in the ‘Feasibility study on detecting, tracking and
understanding emerging trends in drug use’ drawn up by the Centre’s epidemiology
department (see Chapter 1). At the Reitox meeting in June, the focal points’
participation in the joint action on new synthetic drugs was reported.
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Further involvement of the CEECs in the activities of the
EMCDDA and Reitox
The central and east European countries involved in the PHARE project on drug
information systems (DIS) forged a closer relationship with the EMCDDA and the
national focal points in 1998, playing an increasingly active role in the Centre’s
Reitox programme.
Like their counterparts in the EU, the CEEC prototype focal points had the core task
of compiling national reports in preparation for the EMCDDA’s Annual report on
the state of the drugs problem in the European Union 1998 which significantly
broadened the geographical scope of the report. The CEECs also updated
information maps, while national experts from the region were involved in
EMCDDA seminars and projects.
One of the major challenges of the DIS project in 1998 was ensuring recognition
of the CEEC prototype focal points at the highest political levels to render them
sustainable. Although these centres already function (some having a legal basis), the
EMCDDA’s closer involvement in the DIS project and its paper on the role of the
national focal points substantially assisted the process. The candidacy for EU
membership of certain CEECs makes likely the network’s expansion in the near
future. This expansion will pose fresh challenges at a time when current focal point
structures and activities have only recently been consolidated.
Other Reitox activities
Role and financing of national focal points
Reitox working group
Following extended discussions throughout 1997, the EMCDDA’s Management
Board set up a working group in January 1998 to discuss and produce a paper
concerning the role of the Reitox national focal points. The paper focused on the
role and financing of the focal points in general, and in relation to the early-warning
system on new synthetic drugs in particular. The group, composed of the EMCDDA
Bureau members and the Management Board representatives of Denmark, France,
Greece, the Netherlands, Spain and the United Kingdom, met in February, March
and May.
Role and financing
The revised paper, entitled ‘The role and financing of national focal points’,
approved by the Management Board in October 1998, concludes that the focal
points and the EMCDDA have a balanced relationship within the Reitox
community.
The paper states that Member States are responsible for ensuring that core tasks
allocated to the focal points are carried out in a timely fashion and to a high
standard. As focal points are nominated by their Member State, the information
originating from these centres should be regarded as authoritative.
While the paper stresses that there is no fixed model for a national focal point, it
does make clear that they must have both credibility and recognition. The Reitox
network has a firmly established identity as an example of European collaboration
in the drugs field. Although coordinated on a day-to-day basis by a specific
EMCDDA department, the network also has a collective identity based on equal
and open collaboration.
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According to the document, the national focal point (and thus the Member State) is
responsible for carrying out the Reitox core tasks by:
l obtaining the best information available from different national sources;
l maintaining and regularly reviewing a network of national information
sources;
l adding value to this by analysis, interpretation and synthesis prior to
submission to the EMCDDA;
l developing networks and information services at national level;
l improving the quality of national information by adopting instruments and
standards being developed by the EMCDDA in conjunction with national
organisations and focal points;
l seeking to implement standards developed in a similar fashion at national
level; and
l disseminating EMCDDA information nationally and locally.
The Management Board acknowledged that previous focal point funding was
inadequate for the proper execution of recently revised core tasks. A new,
enhanced funding formula was therefore decided for the coming year based on 
a 50-50 split: from 1999, the EMCDDA will raise its contribution to each focal 
point from EUR 40 000 to EUR 100 000 per annum, provided that the Member
State concerned also contributes EUR 100 000 annually to the focal point’s work.
This definitive document on the structure and funding of the focal points has been
an important landmark in the evolution of the Reitox network.
Internalisation and decentralisation
At their meeting in June, the focal points discussed the decentralisation of specific
projects from the Centre as well as their internalisation into the national centres.
This move will affect both the Reitox coordination department, under whose remit
the work will fall, and the focal points themselves who will undertake or supervise
individual projects themselves. Contractual administration will primarily be the
responsibility of the EMCDDA, while the centres will be responsible for fulfilling
their contractual obligations and for negotiating and monitoring tasks they devolve
to national experts and specialists.
Synchronising EMCDDA, focal point, national, regional and local timetables
continues to present difficulties. While the quality of the national reports has
generally improved, some focal points have problems meeting EMCDDA deadlines.
Indeed, the EMCDDA itself has difficulties adhering to agreed timetables when
other priorities compete for attention. While this leads to a level of mutual
understanding, it is to be hoped that meeting agreed deadlines will continue to
improve on both sides in the future.
Chapter 3: Reitox coordination
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Reitox
Reports and output of projects, 1998
Reitox
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l ‘The role and financing of national focal points’
Major meetings organised by the EMCDDA, 1998
Reitox
l 13th meeting of the heads of the Reitox national focal points, Lisbon, 
5 and 6 February
l 14th meeting of the heads of the Reitox national focal points, Lisbon, 
22 and 23 June
l 15th meeting of the heads of the Reitox national focal points, Lisbon, 
19 and 20 October
l Extraordinary meeting of the heads of the Reitox national focal points,
Lisbon, 26 and 27 November
Major meetings attended by the EMCDDA, 1998
Reitox
l ‘IDA Project Steering Committee’, Directorate-General III (Industry),
Brussels, 11 February 1998
l BIRN committee meeting, Belgium, 3 March
l ‘IDA Project Steering Committee’, Directorate-General III (Industry),
Brussels, 1 April 1998
l ‘IDA project: acceptance milestone R1’, Directorate-General III (Industry),
Brussels, 8 July 1998
l ‘IDA project: acceptance milestone R2’, Directorate-General III (Industry),
Brussels, 16 September 1998
l Visit to the Belgian national focal point, Brussels, 7 September
l Visit to the Luxembourg national focal point, Luxembourg, 8 September
l Visit to the Spanish national focal point, Madrid, 15 October
l Visit to the UK national focal point, London, for the launch of the
publication Regulating European drug problems: Administrative measures
and civil law in the control of drug trafficking, nuisance and use (London:
ISDD, 1998), 2 November
l Visit to the Danish national focal point, Copenhagen, 1 December
l Visit to the Swedish national focal point, Stockholm, 2 December
l Visit to the Finnish national focal point, Helsinki, 3 and 4 December
l Carvalhosa, M., and Neaman, R., ‘Reitox — In search of a clear view on
drugs and drug addiction’, IDA report, No 8, September 1998, pp. 4-5.
Chapter 4
New
synthetic drugs
In January 1998, the EMCDDA began
implementing the joint action on new
synthetic drugs adopted on 16 June 1997 in
Brussels by the Council of the European
Union. Tasks carried out in this area during
the year related to priorities 1, 2 and 5 of the
1998 work programme.
At the beginning of the year, matters
relating to the joint action were the
responsibility of an EMCDDA task force
operating in the framework of the Reitox
coordination department. On 1 September
1998, a coordinator formally responsible for
overseeing the implementation of the joint
action and providing support to the
Scientific Committee in the risk assessment
of new synthetic drugs was appointed. A
special section at the EMCDDA was later
created to coordinate all tasks related to
the joint action.
1998 work programme 
New synthetic drugs
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Joint action on new synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the
decisions taken by the EMCDDA Management Board
Joint action and the Reitox network
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activities,
avoiding any duplication of work
Structured synergies and coordination with EU bodies and programmes
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Joint action on new synthetic drugs
Information exchange
In the context of Article 3 of the joint action on new synthetic drugs (exchange of
information), testing began in 1998 of a common reporting format drawn up by the
EMCDDA and Europol in 1997 for collecting and exchanging data in the
framework of the early-warning system on new synthetic drugs established by the
joint action. This test was carried out via an exercise involving the new synthetic
drug MBDB (N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine).
On 27 February 1998, the UK Presidency of the Council of the EU formally referred
MBDB to the EMCDDA for risk assessment under Article 4 (risk assessment) of the
joint action. On 4 March, the horizontal group on drugs of the Council of the
European Union invited all Member States to report any recent incidences or other
relevant information on the drug to Europol or the EMCDDA under the terms of
Article 3.
In response to these initiatives, and to catalogue their results, the EMCDDA and
Europol prepared a joint progress report on the state of implementation of the joint
action, which provided preliminary information on MBDB collected and
exchanged under Article 3 of the agreement. Europol covered production and
trafficking, and the EMCDDA use and possible risks (health and social).
The joint report was submitted to the Chairman of the horizontal group on drugs,
the Council Secretariat and the European Commission prior to its presentation at
the horizontal group on drugs meeting in Brussels on 20 May. The paper also
included information on two other synthetic drugs detected by the early-warning
system, 4-MTA and 2-CT-2. The UK Presidency submitted the joint report to the
European Council meeting in Cardiff, UK, on 15 and 16 June.
Risk assessment
The steering group on new synthetic drugs, set up in November 1997 by the
EMCDDA Scientific Committee to draw up risk-assessment guidelines in the
context of the joint action, met on 16 April, 15 May, 30 September and 
11 November (see Chapter 7). The draft ‘Guidelines for the risk assessment of new
synthetic drugs’ were formally adopted by the Scientific Committee in October
1998.
On 15 July 1998, a high-level expert group on MBDB met in Lisbon. The EMCDDA
commissioned a study on the pharmacotoxicological evidence of the drug which
was later submitted to the steering group and included as a supporting document
for the risk-assessment meeting held in November (see below). The report followed
the structure of Annexes A and B of the risk-assessment guidelines and reviewed the
current scientific knowledge of MBDB. Data on the drug were compared with those
for MDMA since the two substances are similar in structure and action.
A special risk-assessment session was held as an extended EMCDDA Scientific
Committee meeting at the Centre on 9 and 10 November. This gathering was
attended by experts from the EU Member States, the European Commission, the
European Agency for the Evaluation of Medicinal Products (EMEA), London, and
Europol. The meeting adopted the report on all aspects of the risk assessment of
MBDB, reflecting the opinions of the participants on those aspects. The meeting
resulted in a formal ‘Report on the risk assessment of MBDB in the framework of
the joint action on new synthetic drugs’, which also contained a number of
suggestions made by the meeting concerning measures for improving the risk-
assessment of new synthetic drugs in the future.
Control
The ‘Report on the risk assessment of MBDB’ was forwarded to the Secretary-
General of the Council and to the European Commission in November in
accordance with Article 5 of the joint action (procedure for bringing specific new
synthetic drugs under control). Under the terms of this Article, the Council may,
within a month of receiving a risk-assessment report, unanimously adopt a decision
defining the new synthetic drug(s) to be controlled. On 16 December, the European
Commission presented to the Council its formal opinion concluding that it was not
necessary at this point to present an initiative to the Council to propose that MBDB
be submitted to control measures at EU level. Should new factors relating to MBDB
come to light, a new risk assessment should immediately be undertaken.
Joint action and the Reitox network
To involve the Reitox network in the implementation of the joint action, the
EMCDDA circulated a questionnaire to the national focal points requesting
information on MBDB. In addition, it examined other sources, such as the Internet,
data from other relevant organisations and current scientific literature. The
questionnaire also requested ideas from the focal points on the structure, partners
and budget required for implementing the early-warning system.
Structured synergies and coordination with EU bodies and
programmes
During this first year of work on the joint action, the EMCDDA strengthened its
operational links with Europol, the European Commission’s unit responsible for
drug issues and the EMEA. In this context, the EMCDDA made a working visit to the
EMEA in London in September.
Chapter 4: New synthetic drugs
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l The joint action: provides for the establishment of an early-warning system
to identify new synthetic drugs as they appear on the European market;
incorporates a mechanism for assessing the risks of these drugs; and
comprises a decision-making process through which these products may
be placed under control in the EU Member States. The EMCDDA has been
assigned a key role in the detection and assessment of these drugs.
l The joint action concerns new synthetic drugs not currently listed in the
schedules to the 1971 UN Convention on Psychotropic Substances and
which pose a threat to public health. 
l Under Article 3 (exchange of information), information on the production,
traffic and use of new synthetic drugs in the European Union is sent by the
EU Member States to the European Police Office (Europol) in the Hague
and to the EMCDDA in Lisbon via the Europol national units and the
Reitox national focal points respectively. Europol and the EMCDDA then
communicate this information to each other, to their representatives in the
Member States, to the European Commission and to the European Agency
for the Evaluation of Medicinal Products in London.
l Under Article 4 (risk assessment), the EMCDDA shall, at the request of a
Member State or of the European Commission,  convene an expert meeting
under the auspices of its Scientific Committee to assess the health and
social risks posed by the use of, and traffic in, new synthetic drugs and the
possible consequences of prohibition on the basis of the information
received under Article 3. A risk-assessment report covering all aspects is
then produced.
l Under Article 5 (procedure for bringing specific new synthetic drugs under
control), the Council may adopt a decision defining the new synthetic drug
which is to be placed under control measures. The decision is taken on the
basis of the risk-assessment report and within a month of its delivery. The
Member States then implement the necessary control measures in
accordance with their national laws.
l This joint action meets the need to provide the EU with a more flexible and
rapid mechanism for tackling synthetic drugs. However, it does not prevent
any Member State from maintaining or introducing on its territory any
national control measure it deems appropriate once a new synthetic drug
has been identified by a Member State.
Reports and output of projects, 1998
New synthetic drugs
l EMCDDA-Europol ‘Progress report on the joint action on new synthetic
drugs’
l EMCDDA-Europol ‘Improving the mechanisms for the implementation of
Article 3 of the joint action on new synthetic drugs’
l van Aerts, L. A. G. J. M., Mallaret, M., van Laar, M. W., and Rigter, H., ‘The
pharmacotoxicology and neuropsychology of MBDB’
l ‘Report on the risk assessment of MBDB in the framework of the joint
action on new synthetic drugs’
Major meetings organised by the EMCDDA, 1998
New synthetic drugs
l EMCDDA-Europol meeting on the joint action on new synthetic drugs,
Lisbon, 5 March
l Steering group on new synthetic drugs, Lisbon, 16 April
l EMCDDA-Europol meeting on the joint action on new synthetic drugs,
Lisbon, 11 May
l Steering group on new synthetic drugs, Lisbon, 15 May
l High-level expert group meeting on new synthetic drugs, Lisbon, 15 July
l Steering group on new synthetic drugs, Lisbon, 30 September
l Special risk-assessment meeting (extended EMCDDA Scientific
Committee), EMCDDA, Lisbon, 9 and 10 November
l Steering group on new synthetic drugs, Lisbon, 11 November
l Meeting on the early-warning system (Article 3 of the joint action), Lisbon,
26 November
Major meetings attended by the EMCDDA, 1998
New synthetic drugs
l Preparatory meeting on the early-warning system on new synthetic drugs,
Paris, 26 and 27 January
l Meeting of the horizontal group on drugs, Brussels, 20 May
l EMCDDA visit to the EMEA, London, 10 September
Chapter 4: New synthetic drugs
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1998 work programme
Information strategies and communication resources
Chapter 5
Information strategies and
communication resources
The information strategies and
communication resources department
encompasses documentation, publications,
media relations, information technology and
information on drug legislation. In 1998, the
EMCDDA’s work in these fields
corresponded primarily to priority
objectives 2, 4 and 6 of the annual work
programme.
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the
decisions taken by the EMCDDA Management Board
Reitox specific project: Implementing phase for a distributed documentary
database (‘virtual library’)
Priority objective 4
Improving the quality of the Annual report on the state of the drugs problem in
the European Union, the visibility of the work of the EMCDDA and the Reitox
network and the dissemination of the information collected and produced by the
EMCDDA
Production of the Annual report on the state of the drugs problem in the
European Union
Production, translation and dissemination of other publications
Media relations
Website
Follow-up of interchange of data between administrations (IDA) project
Priority objective 6
Developing tools and methodologies for comparing interventions, legislation,
strategies and policies in the European Union
Setting up an easily accessible and comparable database on legal instruments
on drugs
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Implementing phase for a distributed documentary database
(‘virtual library’)
In the framework of the 1997 Reitox work programme and in cooperation with
several of the Reitox national focal points and non-Reitox partners nominated by
the focal points, the EMCDDA launched a project to create a ‘virtual library’. This
library is a pan-European distributed database providing a selection of documents
from existing national databases in a comparable and standardised format. The
library allows bibliographic searches of different sources to be made on one
common database, and prevents duplication and overlap of information among the
EMCDDA and its Reitox partners.
During 1998, the project was further developed and the search engine upgraded. 
A sample database is now available with a selection of documents from the
EMCDDA, France, the Netherlands, Norway, Portugal, Sweden and the United
Kingdom.
Other activities in the field of documentation
The EMCDDA’s Documentation and Information Centre (DIC) provides the
following:
l a reading room with a selection of printed and audiovisual documents, 
CD-ROMs and on-line databases;
l access to the Centre’s internal database (bibliodatabase), to the national
reports provided annually by the Reitox focal points, and to documents
published by the European Commission and other European institutions on
drugs and drug-related issues;
l an electronic information-retrieval service; and
l responses to external requests for information, bibliographic searches and
requests for documents.
The documentary collection
The selection of documents housed by the DIC grew by nearly 1 000 during 1998
to a total of almost 2 700. The holdings are managed using the documentary
software WinLib, in conjunction with the full-text retrieval system STATUS/IQ.
Bibliodatabase
A new section of video materials was added to the existing structure of the internal
bibliodatabase during the year. A common format was also created for all the
specialised bibliographies developed by the Centre’s various projects to facilitate
integration into the bibliodatabase. All the records on this tool are indexed by
keywords, and include abstracts of the most relevant internal reports.
User services
The DIC is increasingly consulted by a wide variety of external users. These include
above all: the Reitox focal points; international, European and regional bodies;
university libraries, academics and students; individual researchers; and
practitioners in the drugs field. The DIC responds to all external requests whether
for scientific information and/or general or institutional information.
Other user information services include:
l an internal bimonthly ‘Documentary review’;
l a serials catalogue; and
l information retrieval by profile from electronic services such as
CompuServe’s Executive News Services and Reuters European Union
Briefing service; additional on-line user services are currently being
investigated.
Production of the Annual report on the state of the drugs
problem in the European Union
On 16 September 1998, the European Parliament demonstrated its interest in the
drug problem in Europe by adopting the report of Anne-Marie Schaffner of the
Parliament’s Committee on Civil Liberties and Internal Affairs on the EMCDDA’s
Annual report on the state of the drugs problem in the European Union 1997 
(see also Chapter 8).
The 1998 annual report, the EMCDDA’s main information vehicle, was published
in English on 18 December 1998. Targeted primarily at policy-makers, the report
assembles data and information from 1997 while updating findings from previous
years. The topics covered include:
l the prevalence of illegal drug use;
l data on drug-related deaths and the incidence of HIV and hepatitis B and C
among drug users;
l data on the availability and supply of drugs;
l existing approaches to demand reduction;
l national strategies and legislation;
l action taken at European level;
l international action; and
l public funding of anti-drug activities.
For the first time, the 1998 annual report also addresses the drug situation in central
and eastern Europe.
At the time of its official launch in Vienna on 18 December 1998, detailed
‘Summary and highlights’ of the annual report were also available in all 11 EU
languages. Electronic files of these ‘Summary and highlights’ can be downloaded
from the EMCDDA website at http://www.emcdda.org/html/ar_98.html/.
Production of other publications
The EMCDDA produces two annual publications — the Annual report on the state
of the drugs problem in the European Union and the General report of activities —
a bimonthly newsletter, DrugNet Europe, a scientific monograph series and the
Insights series. In autumn 1998, the EMCDDA launched a new Manuals series of
publications with the Guidelines for the evaluation of drug prevention (see Chap-
ter 2).
A list of the publications produced by the EMCDDA in 1998 is given below.
Chapter 5: Information strategies and communication resources 
EMCDDA publications, 1998
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Title Series Languages
1998 Annual report on English
the state of the drugs 
problem in the European 
Union
‘Summary and highlights’ All 11 EU languages
of the 1998 Annual report 
on the state of the drugs 
problem in the European 
Union
DrugNet Europe, English, French, German, 
Issues 9-14 Portuguese
Estimation de la Scientific monograph French
prévalence de la No 1
consommation 
problématique de 
drogues en Europe
Evaluating drug Scientific monograph English
prevention in the No 2
European Union
Evaluating the treatment Scientific monograph English
of drug abuse in the No 3
European Union
1997 General report of English, French, German, 
activities Portuguese, Spanish
Guidelines for the Manual No 1 — English
evaluation of drug new series
prevention
1998 publications English, French, German, 
catalogue Portuguese, Spanish
Publicity flyer prepared English, Spanish, 
for EXPO ‘98 Portuguese
EMCDDA presentation All 11 EU languages
brochure
Media relations
In 1998, the Centre continued to receive a steady stream of information requests
from the written and broadcast media across Europe as well as from services in non-
EU countries. This interest resulted in several interviews and articles on all aspects
of the Centre’s work, with special focus on matters relating to drug legislation.
Photographic competition
In September 1997, in the context of its work on the portrayal of drugs in the media,
the EMCDDA launched a photographic competition entitled ‘Can we alter these
images?’. The aim was to provoke reflection on the often negative images used by
the media to portray the drug problem and to focus on more positive approaches
and responses to it.
The competition closed on 1 May 1998 and the winning photographs were
exhibited at the European Union pavilion at EXPO ‘98 in Lisbon from 12 to 30
September 1998. The winners were from the UK, the Czech Republic and France.
An informal briefing on the event for local journalists was held on 12 September.
The winning photographs can be viewed on the EMCDDA web site at
http://www.emcdda.org/html/mediarelations.html/.
Press conferences and press reviews
The EMCDDA organised two press conferences in 1998. The first concluded the
visit to the EMCDDA on 17 July of Director of the US White House Office of
National Drug Control Policy (ONDCP), General Barry R. McCaffrey, and reported
the innovative ideas for US-EU cooperation discussed at the first United States-
European Union Informal Drug Forum (see Chapter 8). The second press
conference was held on 18 December 1998 to launch the Annual report on the
state of the drugs problem in the European Union 1998. It took place at the Federal
Ministry of Labour, Health and Social Affairs, Vienna, in the presence of: Lore
Hostasch, Austrian Federal Minister for Labour, Health and Social Affairs; Marcel
Reimen, Vice-Chairman of the EMCDDA Management Board; Georges Estievenart,
Director of the EMCDDA; and Peter Hacker, Coordinator for Drug Affairs of the City
of Vienna.
Three press reviews were compiled in 1998: two short reviews covering the visit to
the EMCDDA of General McCaffrey, and the Euro-Ibero American Seminar,
‘Cooperation on drugs and drug addiction policies’ held in Oporto, Portugal, in
October 1998 (see Chapter 8); and a review of over 100 pages of articles from the
European Union and central and eastern Europe on the launch of the EMCDDA’s
1998 Annual report on the state of the drugs problem in the European Union.
EMCDDA press conferences and press releases, 1998
Date Title
Press conferences
17 July Visit to the EMCDDA of General Barry R. McCaffrey,
Director of the US White House Office of National Drug
Control Policy (ONDCP), Lisbon
18 December Launch of the 1998 Annual report on the state of the drugs
problem in the European Union, Vienna
Press releases
16 March ‘EMCDDA and UNDCP unite in the fight against drugs —
Memorandum of Understanding between the EMCDDA
and the United Nations International Drug Control
Programme (UNDCP)’
(English, Portuguese)
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5 June ‘UN “Drug Summit”: EMCDDA Director welcomes appeal
for strengthening demand-reduction and information
strategies worldwide’
(English)
11 June ‘UN “Drug Summit”: EMCDDA Director welcomes
demand-reduction declaration as chance to translate
political plans into action’
(English)
26 June ‘Declaration from the EMCDDA on the occasion of the UN
International Day against Drug Abuse and Illicit Drug
Trafficking — 26 June 1998’
(English, Portuguese)
15 July ‘US Drug Tsar to visit EMCDDA for US-EU Drug Forum’
(English, Portuguese)
17 July ‘“By the turn of the century we must replace ideology with
science” says McCaffrey at US-EU Drug Forum’
(English)
10 December ‘EMCDDA 1998 annual report covers new ground’
(English, German, Portuguese)
18 December ‘EMCDDA’s 1998 annual report: new findings’
(Danish, English, Portuguese)
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Website
As a key part of the Centre’s strategy to disseminate its information as broadly as
possible the EMCDDA’s public website (at http://www.emcdda.org) complements
the Centre’s printed publications programme, but adds a new dimension. The
dynamic medium of Internet technology ensures that up-to-date, accessible and
comprehensive information on the Centre and its work is transmitted directly to the
user.
As well as the latest information on the Centre’s activities, the site includes links to
all the Reitox focal points and to the EMCDDA’s other partner organisations, and
details of its publications, including downloadable files of the ‘Summary and
highlights’ of the annual report in 11 EU languages and DrugNet Europe in four
languages. In the first six months since it was re-launched in June 1998, the fully
updated and redesigned site had attracted over 9 000 new visitors.
Follow-up of interchange of data between administrations
project
In May 1998, the interchange of data between administrations (IDA)-Reitox
environment became operational. The IDA programme, managed by Directorate-
General III (Industry) of the European Commission, was established to coordinate
the development and implementation of telematics applications and services to
enable national and European administrations to exchange information on such
areas as health care, social security and employment services, public procurement,
trademarks and customs.
The IDA-Reitox project analysed the information needs of the EMCDDA and the
Reitox community and identified the best ways of establishing information
exchanges between them. The resultant system allows the EMCDDA better to
disseminate, share and exchange information with the Reitox community via new
services, such as:
l thematic discussion groups (newsgroups);
l a closed website for the Reitox community;
l a directory service to find e-mail and postal addresses, telephone and fax
numbers and other contact information;
l central mailing lists;
l secure transfer of files from Reitox community organisations to the EMCDDA
and vice-versa;
l web interfaces with EMCDDA databases (e.g., the exchange on drug
demand reduction action (EDDRA) database);
l a search engine that indexes all the documents (even those in different
formats) located in pre-defined directories and retrieves those that contain
requested key words; and
l a direct telecommunication line between the EMCDDA and the European
Commission allowing the EMCDDA to access Commission services, such as
the Europateam server which contains inter-institutional information.
In order to provide these information services, the EMCDDA acquired new servers
and the software packages Oracle and Netscape SuiteSpot during 1998.
Other activities in the field of information technology
Consolidation of the EMCDDA’s office automation environment
To ensure that all members of staff have up-to-date electronic equipment, the
EMCDDA acquired several new computers and printers in 1998. It also purchased
a new e-mail server and miscellaneous software.
Software development
Apart from reinforcing the Centre’s telematics infrastructure, the information
technology team also acted as technical advisers for many EMCDDA projects
involving software development and its installation. These projects include:
l the EDDRA information system (see Chapter 2);
l the budgetary and financial system (SI2 — see Chapter 6);
l the EMCDDA’s public website; and
l the Centre’s mail management system (Adonis).
Technical advice was also provided for new applications to be developed and
existing applications to be extended in 1999.
Internet/Intranet
During 1998 the EMCDDA established three electronic sites:
l a public website (http://www.emcdda.org);
l a closed Reitox site accessible only to the Reitox community; and
l an Intranet to facilitate internal communication.
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Setting up an easily accessible and comparable database on
legal instruments on drugs
From January 1998, the EMCDDA began focusing on priority objective 6 of its work
programme, to develop tools and methodologies towards the comparison of
interventions, legislation, strategies and policies in the European Union. As a result,
a new post was created in the information strategies and communication resources
department in September to provide legal information on drugs.
Two major projects were launched in this context in 1998:
l a technical feasibility study for a legal database; and
l the production of a CD-ROM.
Both projects respond to the growing interest in legislation on drugs in the European
Union illustrated by the many political initiatives taken by national parliaments and
international institutions, as well as by the growing number of information requests
on the subject received by the EMCDDA from the general public, practitioners and
decision-makers.
Legal database
A study to assess the feasibility — in terms of both content and technical
specifications — of establishing an on-line database of European drug legislation
was completed in 1998. The main aim of the project is to provide easy access to
detailed and comparable information on national and international legislation,
legal measures, policies and strategies on drugs in the EU Member States. The
database will adopt a common structure to identify specific legislative systems and
approaches, allowing users to compare and contrast legal texts, measures and
policies towards various aspects of the fight against drugs and the control of illicit
substances across Europe.
The first phase will focus on legislation, juridical texts, jurisprudence, legal studies
and their analysis. Later phases will add international conventions, Community
laws on drugs and legal and political overviews within the European Union, as well
as legal measures in the countries of central and eastern Europe.
CD-ROM: European Union legal texts on drugs
Work to compile the content of the EMCDDA’s first CD-ROM, European Union
legal texts on drugs, was finalised in 1998. On publication in 1999, the CD-ROM
will contain a selection of over 300 legal acts issued by the European Union
institutions in relation to drugs since 1988, including regulations, directives,
decisions, resolutions, joint actions, conventions, agreements and parliamentary
questions.
Other activities in the field of drug legislation
Legal monitoring system
To enable the EMCDDA to collect detailed legal information on drugs from national
sources, analyse these data and compare them at international level, the EMCDDA
is studying the possibility of setting up a monitoring system in the field of drugs
legislation. This system would ensure that reliable and comparative information is
disseminated to European decision-makers, practitioners in the drugs field and the
general public. To implement such a system will require the establishment of both
a human network of drug-law experts and a technical infrastructure.
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Other activities in this area in 1998 included:
l dissemination of legal information collected and analysed by the Centre
through contributions to internal and external publications and by
responding to queries from the press and the general public;
l an ongoing study on judicial distinctions between quantities of drugs for
personal use and quantities for trafficking;
l legal contributions to the EMCDDA’s task force on the early-warning system
on new synthetic drugs (see Chapter 4); and
l cooperation with EU and international institutions, such as the European
Parliament, the European Commission, the horizontal group on drugs, the
Pompidou Group of the Council of Europe and the United Nations
International Drug Control Programme.
Major meetings organised by the EMCDDA, 1998
Information strategies and communication resources
l ‘IDA Project Steering Committee’, Lisbon, 15 May 1998
l ‘IDA Project Steering Committee’, Lisbon, 9 October 1998
l Meeting of the technical working group of the Translation Centre for the
Bodies of the European Union, Lisbon, 23 November 1998
Major meetings attended by the EMCDDA, 1998
Information strategies and communication resources
l Meeting to set up collaboration with the United Nations International Drug
Control Programme on exchange of information, publications and media
relations, Vienna, 4 and 5 June 1998
Documentation
l Meeting on the Reitox virtual library, Paris, 15 May 1998
l Visit to the Information Centre of the European Environment Agency,
Copenhagen, 13 November 1998
l 10th Annual Conference of the European Association of Libraries and
Information Services on Alcohol and Other Drugs (ELISAD), Paris, 3 and 4
December 1998
Publications
l Frankfurt Book Fair, 6 to 9 October 1998
l Address to the sixth meeting of the European Publishers’ Forum, Frankfurt,
8 October 1998
l Launch of the 1998 Annual report on the state of the drugs problem in the
European Union, Vienna, 18 December 1998
Media relations
l Visit to Directorate-General X (Information, Communication, Culture and
Audiovisual Media) of the European Commission and briefing on EXPO
‘98, Brussels, 17 and 18 March 1998
l Europe Day, EXPO ’98, Lisbon, 2 September
l Euro-Ibero American Seminar, ‘Cooperation on drugs and drug addiction
policies’, Oporto, 8 and 9 October
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Information technology
l ‘IDA Project Steering Committee’, Directorate-General III (Industry),
Brussels, 11 February 1998
l ‘IDA Project Steering Committee’, Directorate-General III (Industry),
Brussels, 1 April 1998
l ‘Workshop on SI2 implementation project: From prototyping to full
production’, European Training Foundation, Turin, 27 April 1998
l ‘Heads of administration and finance meeting on electronic budget and
accounting systems’, European Commission, Brussels, 30 June 1998
l ‘IDA project: acceptance milestone R1’, Directorate-General III (Industry),
Brussels, 8 July 1998
l ‘IDA project: acceptance milestone R2’, Directorate-General III (Industry),
Brussels, 16 September 1998
l ‘Workshop on extended SI2 functionality to general ledger and payments’,
European Training Foundation, Turin, 27 November 1998
Drug legislation
l Session of the Committee on the Environment, Public Health and
Consumer Protection of the European Parliament, Brussels, 16 April 1998
l Session of the Committee on Civil Liberties and Internal Affairs of the
European Parliament, Brussels, 25 to 26 May and 22 to 23 July 1998
l Meeting to set up collaboration with the UNDCP to exchange information
on legislation, Vienna, 4 and 5 June 1998
l Pompidou Group expert meeting, ‘The social costs of drugs’, Strasbourg, 9
to 11 September
l Pompidou Group seminar, ‘Drug-misusing offenders and the criminal
justice system’, Strasbourg, 12 to 14 October 1998
l 42nd meeting of the permanent correspondents of the Pompidou Group,
Strasbourg, 26 and 27 October 199852
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Articles published, 1998
Information strategies and communication resources
l Ballotta, D., ‘EMCDDA to set up legal database’, Newsletter of the PHARE
multi-country programme for the fight against drugs, No 4, January 1998,
p. 5
l Ballotta, D., ‘Fifteen states, fifteen laws’, Narcomafie, supplement to No 8,
October 1998, pp. 10-12
l Carvalhosa, M., and Neaman, R., ‘Reitox — In search of a clear view on
drugs and drug addiction’, IDA Report, No 8, September 1998, pp. 4-5
l Robertson, K., ‘European Monitoring Centre for Drugs and Drug Addiction
profile’, European Journal on Criminal Policy and Research, Vol. 6, No 3,
1998, pp. 457-466.
In 1998, the reorganisation of the EMCDDA’s administrative structure and
procedures — initiated in response to the increasing volume of activities
undertaken by the Centre — was completed. The main points were as follows:
l At its 12th meeting on 8 and 9 January, the EMCDDA Management Board
gave the Director discharge on the implementation of the 1996 budget,
adopted the 1998 budget of ECU 7.6 million (with ECU 2.0 million entered
in reserve) and adopted the 1999 preliminary draft budget of EUR 8.0
million. The 1998 ECU 7.6 million appropriation, which corresponded to
the appropriation available under EU budget line B3-441, reflected an
increase of ECU 0.6 million to meet the financial requirements of
implementing the June 1997 EU joint action on new synthetic drugs (see
Chapter 4). The reserve was lifted in June.
l At its 13th meeting on 2 and 3 July, and in response to comments made by
the Court of Auditors on the implementation of the 1996 budget, the
EMCDDA Management Board adopted an internal financial regulation to
improve the Centre’s financial management. Implementation of this
regulation met with the approval of the European Court of Auditors and the
Centre’s Financial Controller.
l In October and November respectively, the Financial Controller and the
European Court of Auditors visited the EMCDDA to carry out their annual
audit.
l In the fourth quarter of 1998, the EMCDDA received the following two
grants from the European Commission:
— ECU 80 000 to finance the Euro-Ibero American Seminar on
‘Cooperation on drugs and drug addiction policies’ held in Oporto,
Portugal, on 8 and 9 October (see Chapter 8); and
— ECU 11 845 to finance a seminar on ‘Qualitative research: Knowledge
for effective action’ held at the EMCDDA’s headquarters from 29 to 
31 October (see Chapter 1).
l At the end of 1998, the EMCDDA began installing the electronic budgetary
and accounting system SI2 in close cooperation with five other decentralised
EU agencies: the Community Plant Variety Office (Angers); the European
Agency for Safety and Health at Work (Bilbao); the European Foundation for
the Improvement of Living and Working Conditions (Dublin); the Translation
Centre for the Bodies of the European Union (Luxembourg); and the
European Training Foundation (Turin). A Memorandum of Understanding for
a common support service was signed by all the agencies concerned.
Chapter 6
Administration,
finance and logistics
l The Centre recruited five new temporary staff during the year, giving a total
of 40 full-time temporary staff by the end of 1998.
l The ground floor of the EMCDDA’s headquarters was remodelled to create
extra offices to meet this increase in staff numbers.
The budgetary figures for 1998 are given in the tables below. 
Appropriations, 1998
(as at 31.12.1998)
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Title Description (ECU)
1. Expenditure on persons linked to the EMCDDA
(salaries, allowances, missions, etc.) 3 155 000
2. Buildings, material and miscellaneous expenditure 
for operations
investment in property, letting of property and 
incidental costs 246 000
information technology 70 000
goods, furniture and incidental costs 308 000
standard administrative functioning 181 000
postage and telecommunications 150 000
statutory meetings 290 000
Total under title 2 1 245 000
3. Expenditure by the institution in exercising its 
mission
costs of convening meetings 341 845
studies, surveys, consultations and training 772 000
publications 968 000
support for the Reitox network 1 210 000
Total under title 3 3 291 845
10. Other expenses —
Total budget 7 691 845
Title Description % of total 
consumption
1. Expenditure on persons linked to the EMCDDA
(salaries, allowances, missions, etc.) 96
2. Buildings, material and miscellaneous expenditure 
for operations 99
3. Expenditure by the institution in exercising its mission 87
Total consumption (Titles 1, 2 and 3) 93
Credit consumption, 1998
(Commitments)
EMCDDA balance sheet for the financial years 1996 and 1997
(thousand ECU)
Assets 1997 1996 Liabilities 1997 1996
Fixed assets
Fixed assets 3 409 3 345
Fixed capital
Subtotal 3 409 3 345
Own capital 3 421 3 346
Stocks Balance for the 
financial year (1 569) 885
Office 
equipment 12 1 Subtotal 1 852 4 231
Subtotal 12 1
Current assets
Current liabilities
European 
Commission 
subsidy 2 668 160
Balance of Appropriations carried 
sundry accounts over by the budget 
received 207 371 authority 135
Advance on Automatic carry-over 
Portuguese of appropriations 1 930 2 429
Government 
account 298
VAT to be 
recovered 172 213 Sundry accounts due 21 119
Balance on Portuguese
Government account 93
Subtotal 3 047 1 042 VAT to be recovered 172 213
Re-use accounts 15 51
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Cash accounts Counterpart European
Commission subsidy 2 668
Bank 1 209 2 977 Subtotal 4 806 3 040
Imprest accounts 800 534
Transfers in 
progress (1 820) (629)
Cash 1 1
Subtotal 190 2 883
Total assets 6 658 7 271 Total liabilities 6 658 7 271
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EMCDDA expenditure and revenue account for the financial years 1996
and 1997
(thousand ECU)
1997 1996
Revenue
European Commission subsidy 3 632 5 848
Subsidy to be received from the European Commission 160
Miscellaneous revenue 90 131
Total revenue 3 722 6 139
Expenditure
Staff — Title I
Payments 2 517 1 764
Appropriations carried forward 6 128
Buildings, equipment, etc. — Title II
Payments 884 497
Appropriations carried forward 43 540
Operations — Title III
Payments 829 781
Appropriations carried forward 1 881 1 896
Total expenditure 6 160 5 606
Out-turn for the financial year (2 438) 533
Out-turn carried over from previous year 885
Adjustment to out-turn from previous year (81)
Appropriations carried forward and cancelled 92 369
Exchange-rate differences (27) (17)
Balance for financial year (1 569) 885
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The Management Board
The Management Board is the main decision-making body of the EMCDDA. It
meets at least once a year and consists of one representative from each Member
State of the European Union, two representatives from the European Commission
and two persons highly qualified in the field of drugs designated by the European
Parliament.
In 1998, besides its usual agenda items — such as the annual work programme, the
budget and personnel issues — the Management Board adopted a key document
on ‘The role and financing of national focal points’ (see Chapter 3). This paper is
central to the work of the EMCDDA given the vital part the Reitox network of focal
points plays as the backbone of the Centre’s data-collection process and other
activities.
Meetings of the Management Board, 1998
Chapter 7
EMCDDA statutory
bodies
The EMCDDA’s main statutory bodies are the
Management Board, the Bureau and the
Scientific Committee, which all met in 1998.
A summary of the major points discussed and
decisions adopted are given below.
Date Meeting Decisions
8 and 9 12th meeting of the l decision to create a working group to 
January Management Board l produce a paper on the role of the
national focal points for adoption by the
Board
l adoption of the 1997 General report of
activities
l adoption of the 1998 work programme
including the structure of the 1998
Annual report on the state of the drugs
problem in the European Union
l adoption of the 1998 budget of ECU 7.6
million with an increase of five new staff
posts
l adoption of the 1999 preliminary draft
budget of EUR 8.0 million
l discharge on the implementation of the
1996 budget
2 and 13th meeting of the l discussion of the external evaluation of 
3 July Management Board the 1997 annual report, the production
of the 1998 annual report and the
format of the 1999 report
l discussion of the progress of the paper
on the role of the national focal points
l decision to continue to develop the
EDDRA database and to designate it as a
Reitox core task
l request for further information on the
requirements, extent and users of the
legal database
l adoption of the Director’s report on the
measures taken in response to the
comments of the Court of Auditors on
the implementation of the 1996 budget
l adoption of the internal financial
regulation
l adoption of requests for non-automatic
budgetary carry-overs
l adoption of the rules laying down the
composition and procedure of the
EMCDDA Staff Committee
l decision to transfer appropriations from
one chapter of the budget to another
l information on the implementation of
the June 1997 joint action on new
synthetic drugs and the status of the
Scientific Committee’s risk-assessment
guidelines
22 and 14th meeting of the l discussion and adoption of the paper on
23 October Management Board ‘The role and financing of national focal
points’
l discussion of the production of the 1998
annual report and the content and
format of the 1999 report
l decision on translating the various
EMCDDA publications
l discussion of the 1999 work programme
l information on the European
Parliament’s report on the 1997 annual
report (the Schaffner report)
l information on the formal participation
of Norway in the EMCDDA’s activities
l ratification of the decision of the Bureau
to transfer ECU 280 000 from budget
line 3110 to budget line 3510
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The Bureau
The Bureau of the EMCDDA meets five to six weeks before each Management
Board meeting to prepare for the latter in consultation with the Director. In
accordance with Article 2 of Council Regulation (EEC) No 302/93, the Bureau may
also, in between any two meetings of the Board and in consultation with the
Director and Chairman of the Scientific Committee, take decisions unanimously
which are urgent or necessary for the management of the Centre, subject to
ratification by the Board at its next meeting.
In addition, the Bureau, together with the head of the EMCDDA’s administration
department, constitutes the Advisory Committee on Procurements and Contracts
(ACPC) for financial transactions exceeding EUR 46 000. The Director of the Centre
also attends these meetings.
Meetings of the Bureau, 1998
Date Place Decisions
20 January Brussels l noted the Director’s report on the measures
taken in response to the comments of the
Court of Auditors on the implementation of
the 1996 budget
l discussed the presentation of the 1999
preliminary draft budget of EUR 8.0 million
l discussed the need for a contingency plan
in light of the possible non-release of the
1998 reserve
7 May Strasbourg l discussed the agenda for the July
Management Board meeting
l met as the ACPC and gave a favourable
opinion on the contract presented
12 June Lisbon l discussed the documents for the
Management Board meeting of 2 and 3 July
l discussed the publication of the 1998 and
1999 Annual reports on the state of the
drug problem in the European Union and
their translation into the other EU languages
l discussed the progress of the document on
the role of the national focal points
l met as the ACPC, but did not give a
favourable opinion on the contracts
presented
14 September Lisbon l discussed the agenda for the October
Management Board meeting
l approved a transfer of ECU 280 000 from
budget line 3110 to budget line 3510
l met as the ACPC to give a favourable
opinion on the conclusion of the contract
presented
l discussed the 1998 General report of
activities
4 December Lisbon l discussed the 1999 work programme
l discussed the 1999 budget of EUR 7.8
million and the 2000 preliminary draft
budget of EUR 8.8 million
l met as the ACPC and gave a favourable
opinion on the contracts presented
Chapter 7: Statutory bodies
Scientific Committee
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The Scientific Committee is a consultative organ that assists the Management Board
with its opinions and recommendations on scientific matters. The committee
consists of one representative from each of the Member States of the European
Union, although the Management Board may elect up to six other members. The
committee is convened by its Chairman at least once a year. In April 1998, a new
Chairperson, Dr Desmond Corrigan, and Vice-Chairperson, Dr Salme Ahlström,
were elected.
In 1998, the meetings of the Scientific Committee focused mainly on the
implementation of Article 4 (risk assessment) of the June 1997 joint action on new
synthetic drugs (see Chapter 4). The steering group on new synthetic drugs, created
by the Scientific Committee in November 1997, held its first meeting in 1998. The
group drew up draft guidelines for the risk assessment of new synthetic drugs that
were subsequently adopted by the Scientific Committee at its meeting in October.
These guidelines were also presented at the special meeting on the risk assessment
of MBDB held on 9 and 10 November at the EMCDDA headquarters in Lisbon. This
meeting adopted a revised version of the guidelines, as well as a report reflecting
the opinions of the participants on all aspects of the risk assessment of MBDB. This
paper also contained a number of suggestions for improving the future risk
assessment of new synthetic drugs. The report was submitted to the Council, the
European Commission and the Member States on 16 November, and to the
European Council meeting in Vienna on 11 and 12 December.
The Scientific Committee also gave its opinion on the Centre’s 1999 work
programme, and discussed how best to improve the quality of the work of the
national focal points.
Meetings of the Scientific Committee, 1998
Date Discussion
17 April l election of the new Chairperson and Vice-Chairperson of the
Scientific Committee
l discussion of the implementation of the June 1997 joint action
on new synthetic drugs
l confirmation of the composition and mandate of the steering
group on new synthetic drugs
l discussion of the work of the steering group on new synthetic
drugs
l discussion of how to improve the quality of the work of the
national focal points 
1 and l workshop on the ‘Risk assessment of new synthetic drugs’
2 October l adoption of the ‘Guidelines for the risk assessment of new
synthetic drugs’
l report on MBDB
l preparation of the meeting on the risk assessment of MBDB
l discussion of the role of the Scientific Committee as envisaged
in the report evaluating the Annual report on the state of the
drugs problem in the European Union 1997
l further discussion of the quality of the work of the national
focal points
l report on the EDDRA database
9 and l meeting on the risk assessment of MBDB and on the 
10 November implementation of the joint action on new synthetic drugs
l discussion of the preliminary draft of the 1999 work
programme
At the time the Centre was established, six priority partners were identified:
l the United Nations International Drug Control Programme (UNDCP),
Vienna;
l the Pompidou Group of the Council of Europe, Strasbourg;
l the Regional Office for Europe of the World Health Organisation (WHO-
Europe), Copenhagen;
l Europol, the Hague;
l the International Criminal Police Organisation (Interpol), Lyons; and
l the World Customs Organisation (WCO), Brussels.
The EMCDDA participates as observer in the meetings of the UNDCP’s
Commission on Narcotic Drugs, those of the Permanent Correspondents of the
Pompidou Group and in Interpol’s General Assembly. The WHO-Europe, the
UNDCP and the Pompidou Group also participate as observers in the Centre’s
Management Board meetings.
1998 work programme
Partners
Chapter 8
The EMCDDA
and its partners
Activities in 1998 relating to the EMCDDA
and its partners corresponded to priority
objective 5 of the work programme.
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activities,
avoiding any duplication of work
Structured synergies and coordination with EU bodies and programmes
Further involvement of the central and east European countries in the
activities of the EMCDDA and Reitox in the framework of the PHARE
multi-country programme for the fight against drugs
Developing cooperation with Mediterranean and Latin American
countries and with the United States
Progressive participation of Norway in the activities of the EMCDDA
Cooperation with European and international organisations
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Structured synergies and coordination with EU bodies and
programmes
European Council/Council of the European Union
In 1998, the EMCDDA participated as permanent observer in the horizontal group
on drugs of the Council of the European Union, largely in relation to the joint action
on new synthetic drugs (see Chapter 4). The Centre also gave the Council technical
support in drafting a document on drugs and related issues for the European
Council meeting held in Vienna on 11 and 12 December. The meeting’s
conclusions stated: ‘Full use should be made of the expertise of the European
Monitoring Centre on Drugs and Drug Addiction’ in developing further ‘an
integrated and balanced post-1999 drugs strategy’.
European Commission
Secretariat-General
The Secretariat-General Drugs Unit — the EC focal point in the Reitox network —
provided the EMCDDA with details of the action on drugs undertaken by the EU for
inclusion in the Annual report on the state of the drugs problem in the European
Union 1998.
Directorate-General III (Industry)
For details of the interchange of data between administrations (IDA) programme,
see Chapter 5.
Directorate-General V (Employment, Industrial Relations and Social
Affairs)
The EMCDDA was closely involved in preparing for, and evaluating, European
Drug Prevention Week (16 to 22 November 1998), organised by DG V. The Centre
supplied the Commission and national coordinators with its Guidelines for the
evaluation of drug prevention. Drug-prevention initiatives were reported to the
Commission via an EMCDDA questionnaire, facilitating evaluation of the event.
Projects that met the quality criteria were added to the Centre’s EDDRA database
(see Chapter 2).
Directorate-General VII (Transport)
A DG VII high-level group on road safety held the third meeting of its working
group on alcohol, drugs, medicines and driving at the EMCDDA on 28 and 29
September. Twenty participants exchanged information on related projects and
discussed developing an integral approach to the problem of illicit drugs and
driving. The EMCDDA presented its current project, a bibliography and literature
review on the relation between driving and the use of illicit drugs, carried out by
the Irish national focal point, the Health Research Board.
Directorate-General XII (Science, Research and Development)
Cooperation with the European Commission’s COST-A6 working group on
evaluation of treatment in Europe included several meetings to discuss guidelines
for the evaluation of treatment (see Chapter 2).
European Parliament
Key reports
The European Parliament demonstrated its interest and attention to the drugs
problem in Europe in 1998 by producing two reports issued by its Committee on
Civil Liberties and Internal Affairs.
The first, by rapporteur Anne-Marie Schaffner, on the EMCDDA’s Annual report on
the state of the drugs problem in the European Union 1997 was adopted on 16
September in Strasbourg. The Schaffner report:
l welcomed the clear progress made in standardising definitions and data-
collection despite the general lack of common terms and methods in Europe;
l appreciated the attention given to demand reduction and new synthetic
drugs in the annual report;
l called on the EMCDDA to strengthen cooperation between the Reitox
national focal points;
l requested that the Centre provide policy-makers and EU institutions with a
reliable assessment of European anti-drug strategies by developing its work
on legal information; and
l placed high priority on cost-benefit analyses of national drug policies.
The second report, by rapporteur and chairperson of the committee Hedy
d’Ancona, adopted in Strasbourg on 6 October, focused on enhancing European
cooperation on drugs in light of the United Nations General Assembly Special
Session on Drugs (Ungass) held in June 1998. The d’Ancona report:
l appealed to Member States for a more pragmatic and social approach to the
drugs problem;
l emphasised the need for treatment and rehabilitation, and for more
resources in these areas;
l pledged support for a more comprehensive global approach to the problem
including prevention, information, education and harm reduction;
l called on the Centre to develop indicators with which to assess the drug
situation;
l urged the Member States to collaborate in compiling comparable data; and
l underscored the need for evaluation of different anti-drug strategies, analysis
of the discrepancies between law and practice, and greater attention to be
paid to central and eastern Europe and Cyprus.
Visits to the EMCDDA
Delegations from the Committee on Civil Liberties and Internal Affairs and the
Committee on the Environment, Public Health and Consumer Protection visited the
Centre on 3 March and 25 September 1998 respectively. Both Committees were
involved in the Parliament’s evaluation of the EMCDDA’s 1997 annual report.
European Union agencies
In its capacity as Chair of the decentralised EU agencies, the EMCDDA held a
meeting of the 11 Directors in Lisbon on 13 July. Among the topics discussed were:
l financial and personnel issues;
l inter-agency cooperation;
l the agencies’ role in the accession of central and east European countries
(CEECs) to the EU; and
l a meeting with Carlo Trojan, Secretary-General of the European
Commission, scheduled for early 1999.
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Further involvement of the central and east European
countries in the activities of the EMCDDA and Reitox
PHARE multi-country programme for the fight against drugs
The EMCDDA joined over 50 participants at the seventh liaison group meeting of
the multi-country programme in Riga, Latvia, on 26 and 27 February. The meeting:
l examined the results of the programme to date;
l plotted its future orientations;
l analysed its impact; and
l helped strengthen links between programme coordinators, project managers
and representatives of the EC and other international organisations.
The programme’s future priorities include:
l information collection;
l institution-building;
l harmonising legislation;
l cooperation between the EU and CEECs on demand and supply reduction;
l creating integrated policies in cooperation with the EMCDDA;
l preventing the illicit production and abuse of synthetic drugs; and
l preventing drug trafficking in the Balkan region.
PHARE project on technical assistance to drug demand reduction
As one of the project evaluators, the EMCDDA attended the first regional seminar
of the PHARE project on technical assistance to drug demand reduction in Warsaw,
Poland, from 16 to 18 April 1998. The main objectives of the project, which
includes four sub-regional programmes, are to:
l strengthen community prevention, outpatient treatment, harm reduction and
innovative training and to establish resource centres in these areas;
l develop strategies to adapt to the changing national political and economic
situations; and
l increase capacities for designing, implementing, managing and evaluating
demand-reduction projects in the priority areas identified.
The evaluation group requested that the sub-regional projects:
l use the EMCDDA’s Guidelines for the evaluation of drug prevention
(see Chapter 2);
l evaluate policy development by interviewing decision-makers about the
programme’s impact; and
l design questionnaires to measure capacity development among the key
actors.
A special training session on the use of the guidelines was held at the project’s
methodological seminar in Sofia, Bulgaria, from 26 to 30 May 1998.
The EMCDDA hosted a meeting of the sub-regional project on harm reduction on
3 and 4 September, with the participation of experts from the Czech Republic,
Slovenia and the Former Yugoslav Republic of Macedonia (FYROM).
A first evaluation report, covering the period from January to June 1998, was
presented by the evaluation group in September.
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PHARE multi-country project on drug information systems (DIS)
The DIS is assisting the countries of central and eastern Europe in developing an
information network similar to the Reitox system by setting up prototype national
focal points in each participating country. In 1998, these focal points participated
in the EMCDDA’s activities by:
l compiling national reports in preparation for the EMCDDA’s 1998 Annual
report on the state of the drugs problem in the European Union, significantly
broadening the report’s geographical scope;
l updating information maps; and
l attending EMCDDA seminars and projects (see Chapter 3).
On 3 and 4 December, representatives of Directorate-General IA (External
Relations) of the European Commission visited the EMCDDA to explore ways of
integrating the PHARE countries more directly in the Centre’s work.
Developing cooperation with Mediterranean and Latin
American countries and with the United States
Latin America
Euro-Ibero American seminar on ‘Cooperation on drugs and drug policies’
Cooperation between the European Union and Latin America in the drugs field was
the topic of a Euro-Ibero American Seminar held on 8 and 9 October in Oporto,
Portugal, under the patronage of Vice-President of the European Commission,
Manuel Marín. Conceived and promoted by the President of the Portuguese
Republic, Jorge Sampaio, the event was organised in cooperation with the
Portuguese Government and with the support of the European Commission and the
EMCDDA.
In anticipation of the Ibero-Latin American Summit, convened in Oporto from 16
to 18 October, and the Euro-Latin American Summit, to be held in Rio de Janeiro
in 1999, the seminar:
l identified new and better forms of cooperation in the field of information on
drugs, demand reduction and inter-city cooperation;
l drew up recommendations to inspire innovative and concrete projects
between the two regions at the subsequent Summits;
l led to the adoption of the ‘Oporto Declaration’, which was annexed to the
conclusions of the Ibero-Latin American Summit; and
l proposed the EMCDDA as the bridge between Europe and Latin America in
the field of drugs and as a facilitator of forums presenting demand- and
harm-reduction initiatives.
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Relations with Brazil
In March 1998, the Director of the EMCDDA met with representatives of the
Brazilian National Coordination Unit on Drugs in Brasilia. The meeting:
l identified areas of mutual interest;
l discussed bilateral exchanges of information and experience; and
l broached inter-regional cooperation on drugs in Latin America, in particular
with the Mercosur group of countries.
United States
United States-European Union Informal Drug Forum
Director of the US White House Office of National Drug Control Policy (ONDCP),
General Barry R. McCaffrey, visited Lisbon on 17 July to participate in the first
United States-European Union Informal Drug Forum at the EMCDDA. The forum,
involving some 30 high-level US and European officials:
l described the state of the drugs problem on both sides of the Atlantic;
l examined US and EU drug strategies;
l discussed mutual US-EU drug-policy perspectives; and
l proposed examining problems of data collection, improving the tracking of
global drug trends, opening access to the US national drug clearing-house,
and sharing experience in developing performance and outcome measures
of policies and interventions.
The forum was followed up by a working visit from John Carnevale, Director of the
ONDCP’s Office of Budget, Research and Evaluation, from 2 to 4 November 1998.
Participation of Norway in the activities of the EMCDDA
In 1998, following the decision in 1996 to launch a formal procedure allowing it
to participate in the EMCDDA’s activities, Norway took part in some of the
technical working groups of the Centre and in the meetings of the Management
Board, Scientific Committee and the Reitox national focal points.
European and international organisations
Cooperation between the EMCDDA and the World Health
Organisation in the evaluation of demand-reduction activities
See Chapter 2.
Cooperation between the EMCDDA and the United Nations
International Drug Control Programme
in the field of data collection
Memorandum of Understanding
A Memorandum of Understanding (MOU) between the EMCDDA and the United
Nations International Drug Control Programme (UNDCP) was signed on 13 March
in Vienna by EMCDDA Director, Georges Estievenart, and UNDCP Executive
Director, Pino Arlacchi. The MOU formally establishes cooperation between the
two bodies in accordance with the principles of the United Nations Charter and as
foreseen by Article 12 of the Council regulation setting up the EMCDDA.
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The Memorandum unites the two organisations in their efforts to:
l improve data collection and analysis;
l develop and promote data-comparison methods;
l enhance the dissemination of information; and
l promote optimal use of available information and resources, regular
consultation and exchange of technical experience.
The terms of the MOU will be reviewed in 2000.
United Nations General Assembly Special Session on Drugs
The EMCDDA participated in the United Nations General Assembly Special Session
on Drugs which took place in New York from 8 to 10 June. The special session
adopted a draft declaration on the guiding principles of drug demand reduction and
a political declaration in which all Member States committed themselves to
establish and implement demand-reduction policies until the year 2008. The
Director of the EMCDDA addressed the Committee of the Whole and endorsed the
guiding principles as giving ‘a real chance to translate political intentions into
concrete action and hard facts’.
Joint activities between the EMCDDA and the Pompidou Group
Memorandum of Understanding
In 1998, the EMCDDA and the Pompidou Group drafted an MOU to determine
areas of collaboration and define the field of study for each organisation. The MOU
will be completed in 1999.
Permanent Correspondents
The EMCDDA participated as observer in the 41st and 42nd meetings of the
permanent correspondents of the Pompidou Group from 5 to 7 May and 26 and 
27 October at the Council of Europe in Strasbourg. The discussions focused on the
work of the Pompidou Group’s epidemiology sub-group (particularly on how to
avoid overlaps with the work of the EMCDDA in this field) and on other projects
relating to the social costs of drugs, drug misusers and the penal system to be
undertaken in 1999.
City-report guidelines
The EMCDDA participated in the revision of the Pompidou Group’s city-report
guidelines which are used as a basis for its multi-city study on drug misuse trends.
The Centre’s involvement was aimed at improving compatibility between the
Pompidou Group guidelines and those used by the EMCDDA and the Reitox
network in the compilation of national reports.
Europol
Much of the cooperation between the EMCDDA and Europol in 1998 centred
around their shared role, as defined under the terms of the June 1997 joint action
on new synthetic drugs. The joint action grants equal responsibility to the EMCDDA
and Europol for establishing an early-warning system to collect and exchange
information on the production, traffic and use of new synthetic drugs, taking
account of the respective mandates of the two bodies (see Chapter 4).
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Interpol
In 1998, cooperation between the EMCDDA and Interpol was limited to Interpol’s
contribution to the drafting of the 1998 annual report. A representative from the
Centre attended Interpol’s 67th General Assembly in Cairo from 22 to 27 October.
World Customs Organisation
Although no formal meetings were held in 1998 with the World Customs
Organisation, the WCO contributed to the EMCDDA’s 1998 annual report.
Other activities
Meetings with Portugal’s Minister for drugs
The EMCDDA held its first meeting on 9 March with the new Portuguese Deputy
Minister responsible for the drugs portfolio, José Sócrates. The Minister then paid a
working visit to the EMCDDA on 17 April.
Visit of Belgian Minister responsible for the Brussels region
Belgian Minister responsible for the Brussels region, Eric Tomas, visited the
EMCDDA on 18 May for a fact-finding session on the agency’s activities. Minister
Tomas:
l requested information on data-collection methods to gain an insight into
how information from different sources could be better centralised at
regional and national level;
l proposed that a harmonised data-collection system at national and European
level would help the EMCDDA accomplish its tasks fully;
l asked that policy-makers in Member States be provided with better
information to draft policies; and
l stated his wish to act as a link between the Centre and his colleagues
responsible for health at federal and Community level to improve Belgium’s
contribution to the Centre’s work.
Major visits and meetings hosted by the EMCDDA, 1998
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Date Visit
Structured synergies and coordination with EU bodies and programmes
3 March Visit of the Committee on Civil Liberties and Internal Affairs
of the European Parliament 
4 March Liaison meeting with Directorate-General XII (Science,
Research and Development) of the European Commission
5 March Meeting with Europol on the early-warning system on new
synthetic drugs
11 May Meeting with Europol on the June 1997 joint action on new
synthetic drugs
13 July Meeting of the Directors of the European Union agencies
25 September Visit of the Committee on the Environment, Public Health
and Consumer Protection of the European Parliament
28 and Working group on alcohol, drugs, medicines and driving 
29 September of Directorate-General VII (Transport) of the European
Commission
Further involvement of the central and east European countries in the
activities of the EMCDDA and Reitox in the framework of the PHARE
multi-country programme for the fight against drugs
26 March Visit of the Ambassador of Slovenia to Portugal, Matjaz
Kovacˇicˇ 
3 and 4 December Visit of representatives of Directorate-General IA (External
Relations) of the European Commission to discuss the greater
integration of the PHARE countries in the Centre’s work
Developing cooperation with Mediterranean and Latin American 
countries and with the United States
12 May Visit of a delegation from the Inter-American Drug Abuse
Control Commission (CICAD)
17 July Visit of General Barry McCaffrey, Director of the US White
House Office of National Drug Control Policy (ONDCP)
2 and 3 November Visit of John Carnevale, Director, Office of Programmes,
Budget, Research and Evaluation, US White House Office
of National Drug Control Policy (ONDCP)
Other visits and meetings
15 April Visit of the Ambassador of Finland to Portugal, Matti
Häkkänen
17 April Visit of the Portuguese Deputy Prime Minister responsible
for the drugs portfolio, José Sócrates
6 May Visit of the Committee of Health and Social Affairs of the
Finnish Parliament 
18 May Visit of the Belgian Minister responsible for the Brussels
region, Eric Tomas
26 May Visit by a delegation of the Institut des Hautes Etudes de la
Sécurité Intérieure (IHESI), Paris
24 June Visit of the Ambassador of the Permanent Mission of
Austria to the United Nations, Irene Freudenschuss-Reichl
29 June Visit of the General Director of the Swedish Institute for
Public Health, Agneta Dreber
Major EMCDDA events, 1998
Developing cooperation with Mediterranean and Latin American 
countries and with the United States
Date Place Event
17 July Lisbon US-EU Informal Drug Forum 
8 and 9 Oporto Euro-Ibero American seminar on 
October ‘Cooperation on drugs and drug addiction
policies’
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Cooperation with the United Nations International Drug Control
Programme
Date Place Event
13 March Vienna Signing of a Memorandum of Understanding
between the EMCDDA and the United
Nations International Drug Control
Programme (UNDCP)
International cooperation
8 to 10 June New York UN General Assembly Special Session on
Drugs (Ungass)
26 June International Day Against Drug Abuse and
Illicit Drug Trafficking
Other events
18 December Vienna Launch of the 1998 Annual report on the
state of the drugs problem in the European
Union
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